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1     The assessment of the risk/benefit ratio (RBR) of experi-
mental treatments in oncology by Institutional Review Boards 
(IRBs)  
 
 
 
1.1     The assessment of the risk/benefit ratio 
 
In many countries, the law nowadays requires that researchers and doctors 
need to obtain the informed consent of subjects or patients before involving them in 
an experiment or initiating a medical plan. In case of medical experiments the 
informed consent has often to be given by signing a form. The requirement to obtain 
informed consent is based on the principle of respect for the autonomy of persons. In 
the analysis by Faden & Beauchamp (1986), informed consent is an autonomous 
action by a subject or a patient who authorizes a professional to involve the subject 
in research or to execute a medical plan. The most important condition for giving 
informed consent is substantial understanding. A patient who is asked to participate 
in a trial needs to understand the information about the risks, burdens and benefits of 
the experimental treatment. Medical researchers are only allowed to start a trial if 
they obtained the approval of an Institutional Review Board (IRB). IRBs have to 
examine (1) the scientific quality of a trial (its originality, importance, feasibility and 
methodological soundness), (2) the ratio between the risks and the benefits (RBR) of 
a trial, and (1) the quality of the information provided to potential research subjects 
and the quality of the procedures for obtaining consent.  
 
The literature agrees to a great extent on the content and preconditions of 
informed consent (Appelbaum et al., 1987; Levine, 1988; Faden & Beauchamp, 
1986). This is certainly not the case with respect to the assessment of the ratio 
between the risks and the benefits (RBR) of the trial. “What exactly is an RBR? We 
all think we know the answer, but do we?” That question led Ernst and Resch to 
conduct a Medline search (1986 to June 1994). They found 281 papers in which the 
term ‘risk-benefit ratio’ or more or less synonymous terms were used. Their 
conclusion was that everyone seemed to take the definition for granted, yet no-one 
actually provided one (Ernst & Resch 1996). This problem had already been 
signaled by other authors. Meslin (1993a,b) identified the assessment of the 
risk/benefit ratio and lack of consultation on the criteria IRBs use in their 
evaluations as weak links in the evaluation process. Levine – the other author who 
thoroughly analyzed the problems surrounding the RBR assessment – came to 
similar conclusions (Levine, 1978, 1986). 
 
Thousands of research protocols must have been approved by IRBs in the 
last decades. The findings of the above-mentioned authors promt the question how 
IRBs actually come to conclude that the RBR of a trial is ‘reasonable’, proportional’ 
or ‘favorable’.  
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The functioning (Cooke & Tannenbaum, 1977; Gilbert et al. 1989; Hall, 
1991; Miller, 1989; While, 1996) and decision making (Goldman & Katz, 1982; 
Levine, 1984) of Institutional Review Boards (IRBs) has been the subject of limited 
study. Generally speaking, a great deal of diversity, variability and inconsistency is 
found when comparing the decision making of different IRBs (Foster, 1995; Foster 
et al., 1995; Gilbert et al., 1989; Harries et al., 1994, Levine, 1978, 1986). A study of 
11 IRBs in the Netherlands showed that most IRBs spend 15 minutes or less 
discussing a research protocol, including the scientific evaluation (Berghmans et al., 
1996; 1997). The most important norms and principles for evaluation are the 
risk/benefit ratio, scientific issues and the information given to research subjects. If a 
protocol is found wanting in any of these respects, there is a strong argument for 
withholding approval. The authors conclude that the protection of research subjects 
against excessively risky and/or burdensome research is taken very seriously by 
IRBs. Aspects closely related to protecting the interests of research subjects are the 
most important in the evaluation process. These include risk/benefit ratio, the way 
research subjects are recruited, inclusion and exclusion criteria, protecting 
vulnerable groups of patients, and scientific issues including questions of design and 
analysis. Although most IRB members set great store by the risk/benefit ratio and 
scientific issues, they also find them difficult to evaluate. This is also stressed in 
other studies (Bjune & Gedde-Dahl, 1993; Meslin, 1990; Meslin et al., 1994).  
Not only do IRB members have difficulty identifying the relevant risks and 
benefits of a particular protocol, they also find it difficult to compare those risks and 
benefits because (1) the nature, extent and the duration of risks and benefits are often 
uncertain, (2) the nature of the various risks and benefits is very diverse, and (3) all 
of the risks accrue to the research subjects, while some of the benefits accrue to 
future patients and/or to medical science. However, although the literature makes 
clear that IRB members do not find it easy to assess the RBR, next to nothing is 
known about how the RBR is assessed. 
 
 
1.2     Background of the research 
 
In our opinion the lack of consensus on the content of, and categories and 
criteria for evaluating the RBR, causes that IRB evaluations, although usually based 
on long-term clinical experience, are unavoidably subjective and intuitive. The lack 
of shared categories and criteria makes it difficult to trace and discuss differences of 
opinion within an IRB, and thereby reduces the chances that the evaluation of the 
ratio between risks and benefits will play a prominent role in the final decision 
regarding the ethical acceptability of the research. This is why we decided to design 
the research: The assessment of the risk-benefit ratio of experimental treatments in 
oncology by Institutional Review Boards as a part of their evaluation of the ethical 
acceptability of these treatments.  
We had some intuitions about why assessing the RBR is so difficult. These 
we wanted to examine empirically. Firstly, RBR concerns risks and benefits that 
have impact on different dimensions of the health or quality of life of the research 
subject. We inclined to agree with those authors who think that these risks and 
benefits are incommensurable. The problem of incommensurability is aggravated 
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because the benefits not only accrue to the research subjects, but also to future 
patients and medical science. Secondly, the weighing of risks and benefits always 
takes place within a certain context. Decisions about the RBR of a trial depend on 
whether there are alternative treatments and on the quality of these alternatives. 
 
 
1.3     Aims of the research  
 
The aims of the research we developed were: 
 
(1) to provide insight into the factors that play a role in balancing the 
heterogeneous and incommensurable burdens and benefits of experimental 
treatments in oncology and that could explain the possible differences in 
evaluations between members of an IRB; 
(2) to provide insight into the impact that judgments on the diverse evaluative 
dimensions of experimental treatments (scientific importance, soundness, 
originality, side effects, duration, quantity of tumor remissions, symptom-
free period, etc.) have on the final decision about the acceptability of these 
experiments; 
(3) to contribute to increasing the transparency and justifiability of judgments by 
IRBs about the proportionality of benefits and burdens of experimental 
treatments in oncology and thereby to enable IRBs to monitor the 
consistency in their judgments and decisions in regard to different research 
protocols; 
(4) to provide insight into what from an ethical point of view should be the 
relation between the principle of respect for autonomy – the liberty of 
research subjects to form, on the basis of their personal preferences and 
values, their own judgment about the proportionality of benefits and burdens 
of participating in a research – and the principle of non-maleficience that 
puts the IRBs under the obligation to make a general judgement of the ethical 
acceptability of the research; 
(5) to contribute to the insight into the feasibility of the legal obligation of IRBs 
in the Netherlands to determine the proportionality of the ratio between 
benefits and burdens of medical experiments with humans 
 
 
1.4     Main research question 
 
Experimental treatments in oncology differ from other experimental 
treatments in that the risks associated with the treatments are often quite serious. The 
difficulties in determining the ratio between risks and benefits are therefore more 
prominent in clinical oncology than in other medical fields. That is why we decided 
to study the RBR assessment by IRB members and IRBs of clinical cancer trials.  
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The main research question of this study was: 
 
What risks and benefits do IRB members identify in Phase II and III cancer 
clinical trials, how do they estimate and evaluate these risks and benefits, and 
what is the relationship of the evaluative dimensions of risks and benefits (e.g. 
divers physical, psychosocial risks and benefits to participating patients) with 
the RBR assessment and the ethical acceptability of these experiments?  
What other factors determine these assessments and can IRBs assess the 
heterogeneous and incommensurable risks and benefits? And what does it mean 
when they cannot?   
 
 
1.5     Study design 
 
The study we designed is a four-part investigation designed to gain greater 
insight into RBR assessments of Phase II and Phase III cancer clinical trials. The 
first stage of the research involved conducting semi-structured interviews with 53 
IRB members from IRBs at six research hospitals and specialized cancer centers in 
the Netherlands to determine their attitudes, beliefs and experiences in evaluating 
the RBR of Phase II and III cancer clinical trials in general. In the second stage of 
the study, 43 and 41 of these IRB members evaluated two protocols (a Phase II and a 
Phase III clinical trial) by means of a questionnaire. In the third stage, in-depth 
interviews were conducted with 35 of the IRB members from the second stage about 
the protocol evaluations that they had carried out in stage two. The final stage of the 
study involved observation and analysis of the meetings of the full IRBs of two of 
the participating hospitals, during which the two protocols evaluated in stages 
two/three were discussed. Part of the results from the second through fourth stages 
of this investigation are not described in this report, but will be reported in 
subsequent papers.  
 
One of the most important decisions we made in designing our study was to 
work with closed questions as well as open-ended questions in the questionnaires 
and interviews. Churchill et al. (2003) who also interviewed IRB members about 
how they assess benefits, used only open-ended questions (e.g. an open-ended 
question about benefit: “There are several kinds of benefits that might be associated 
with research. What kinds of benefits does your IRB look for when reviewing a 
study?”). According to Churchill et al., the advantage of this approach is that the 
respondents’ answers are not restricted to choices pre-determined by the 
investigator. This was particularly important to them, as they wanted to know what 
people would say without any prompting. By providing IRB members also with 
closed questions, we hoped to attain two other goals. First, to make the data obtained 
by the questionnaires and the interviews comparable and thus to be able to analyse 
the data in a quantitative way. Second, to provide the IRB members with a 
‘language’ in which they could articulate their implicit decisions and what they find 
relevant and not relevant to include in their assessment.  
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1.6     Content of this report 
 
In Chapter 2 the conceptual model that has been developed for the study will 
be described. In Chapters 3 to 6 the empirical and empirical-ethical studies will be 
presented. The article in Chapter 3 has been published; the others are under primary 
or secondary review. Chapter 7 summarizes the main results of the study and 
discusses these in light of the conceptual model.  
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In this chapter the conceptual framework and the assessment model 
developed for the research will be described. The operationalization of the concepts 
and the different blocks of the model are described more extensively in the Method 
and Subjects sections of the various articles (see Chapters 3-6) and in the 
manuscripts that are in preparation.  
 
 
2.1 The conceptual frameworks and assessment models of Katz, Levine and 
Meslin   
 
The most important contributions to the study of RBR assessment of medical 
research involving humans are without doubt those of Levine and Meslin (Levine, 
1978, 1986; Levine et al., 1884; Meslin, 1989; Meslin, 1990; Meslin, 1993a,b; 
Meslin et al. 1994). Levine (1986) developed a set of categories to distinguish 
between risks and benefits for participating patients, for future patients and for 
society at large (scientific progress). These categories have been further refined by 
distinguishing between different kinds or dimensions of risks and benefits for 
participating patients (e.g. physical, psychological, social). Meslin (1989) devoted 
special attention to the process of risk assessment by IRB members. He identified 
three ‘decision-making processes’ in risk assessment: identification, estimation and 
evaluation of risks. Risk consists of an estimation of the chance and the magnitude 
of the possible harm. Chance can be further divided into an objective and a 
subjective probability estimation. This distinction is necessary because often there 
are not enough empirical data available, or the persons called upon to evaluate these 
data are prejudiced. Also, subjective considerations would influence the risk 
assessment, because values that were attributed to the objective estimations of the 
risk of harm determine what is a considered to be a risk, and whether it can– after it 
is assessed as harm –be evaluated as acceptable or not acceptable. This view of the 
process of risk assessment forms the basis of the four-cell matrix that Meslin has 
made to improve risk assessments by IRBs (see Table 2.1).  
 
 
Table 2.1: A proposed matrix for risk judgements in medical research(Meslin, 1989) 
 
 CONSIDERATIONS 
 Objective Subjective 
EXPRESSION 
OF RISK 
  
Probability of harm Objective probability  
of harm 
Subjective probability  
of harm 
Magnitude of harm Objective  
magnitude 
Subjective  
magnitude 
 
In designing our research on how IRB members make their RBR assessments, we 
made extensive use of Katz’s and Levine’s taxonomies of the kinds of risks and 
benefits and Meslin’s model of the process of risk assessments. However, the aim of 
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these authors in developing these taxonomies and models was not to provide a 
framework for describing the actual process of risk/benefit assessment by IRBs; they 
hoped that IRBs, by using these instruments, would improve the quality of their 
assessments. We believed that these taxonomies and models were not alien to the 
manner in which IRB members actually come to their RBR assessment. Meslin 
acknowledges this when he said that IRBs already apply a sort of risk assessment, 
because IRBs ask researchers to describe what kind of risks and benefits to human 
subjects will result from participation in a trial (Meslin, 1989).  
 
 
2.1      Supplements and modifications 
 
In order to be able to investigate the whole assessment and evaluation 
process that – as we assumed – takes place during the RBR assessment of medical 
research protocols, it is first necessary to describe – as far as possible – all stages of 
the process. Secondly, it is necessary that all the factors that influence – as we 
expected – the assessment also are incorporated in the model. The taxonomies of 
risks and benefits developed by Katz and Levine (1984) and Levine (1986), 
elements from Meslin’s risk assessment model and his four-cell matrix to improve 
the risk assessments of (Meslin, 1989, 1990), were the starting-points for the 
conceptual model we developed (see Figure 2.1). These starting-points were 
complemented with insights from the theory of interactive evaluation and decision 
making of Straver and Van Luijn (Van Luijn & Straver, 1994; Van Luijn, 1996), 
insights from the descriptive approach of psychological decision making in 
cognitive psychology (see a.o. Koele & Van der Pligt, 1993; Harte & Koele, 1997) 
and insights from the empirical literature on the RBR assessment by IRBs and IRB 
members of human subject research.  
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Theory of interactive evaluation and decision making 
The theory of interactive evaluation and decision making integrates the 
theory of coping with stressful life events (Lazarus & Folkman, 1984; 1991) with 
that of decision making under stress (Janis and Mann, 1977). In the theory of coping 
with stressful life events there is (preceding coping as such) a judging and evaluative 
process that consists of two parts: a primary and a secondary appraisal. The primary 
appraisal refers to the perception, judgment and evaluation of an event as stressful 
with respect to the well-being of the person. The secondary appraisal refers to the 
question whether something can be done to take away the threat. The theory about 
decision making under stress (Janis and Mann, 1977) deals with the strategies people 
choose to come to a decision when emotional aspects and/or time pressure play a 
role. In the theory of interactive evaluation and decision making both theories are 
integrated. Hereby the decision-making strategies in the theory of Janis and Mann 
are placed in a context in which person-related and context-related factors determine 
the judgment, evaluation and decision-making process. This approach was used in 
this study as a general decision-making theory to understand and investigate the 
RBR assessment by IRB members of clinical trial protocols. It is complemented 
with the insights of the descriptive approach of decision making in cognitive 
psychology.  
 
Descriptive approach of decision making 
Decision-making behavior can be studied from different perspectives. The 
most important distinction is that between normative and descriptive approaches 
(Koele & Van der Pligt, 1993; Harte & Koele, 1997). In the normative approaches 
the decision problem is well defined and there are axiomatic theories that prescribe 
which decision a rational person should make to maximize the possibility to reach a 
certain goal. The descriptive approach is not interested in what rational subjects 
should do, but what subjects in reality do. The aim is instead to understand and to 
explain how individuals cope with available information to come to a decision. The 
descriptive approach considers individual differences in decision making not as 
deviations from normal behavior, but as relevant conceptual differences that can be 
explained by factors that influence the decision-making process, such as 
motivational, cognitive and emotional factors, time-related, and context factors, and 
factors that correlate with the complexity of the task that must be performed.  
 
 
2.2      Conceptual framework and assessment model of the present study 
 
The conceptual model of this study was developed on the basis of the above-
mentioned conceptual frameworks and theoretical models, and by drawing insights 
from the empirical studies into the RBR assessment by IRBs and IRB members. As 
can be seen in Figure 2.1, the model identifies several stages within the decision-
making process and several factors which may influence the process. Not visible in 
Figure 2.1 is that we conceptualized a separate process of identification, estimation 
and evaluation of the risks and of the benefits of the research for the participating 
patients. The same is true for the risks and benefits of the research for future patients 
and medical science (or society). Although theoretically there must be six separate 
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processes, in reality there are only four, because normally there are no research risks 
for future patients and/or society.
1
 We expected that these four processes first take 
place separately for: (1) the risks of the research for the participating patients, (2) the 
benefits of the research for the participating patients, (3) the benefits of the research 
for future patients, and (4) the benefits of the research for medical science (or 
society). In a second stage the outcomes of those four evaluation processes, namely 
four evaluations, will be weighed against each other.  
In the case of Phase III studies not only the ratio between the risks and 
benefits of the experimental arm must be evaluated, but also the risks and benefits of 
the control arm. This means that the above-described process actually will be 
repeated. The goal of the repetition is to determine whether the RBR of the 
experimental arm is not too different from the RBR of the control arm with respect 
to the risks and benefits to the participating patients. When both arms differ a great 
deal in this respect, it is unethical to let the study take place. Although the above-
described process takes place again, there are not three but only two different 
identification, estimation, and evaluation processes of the risks and benefits of the 
control arm, while it is not necessary to weigh the risks and benefits for future 
patients and/or society. The control arm consists most of the time of the standard 
treatment already evaluated when the standard treatment was itself experimental. 
 
In the rest of this section the different concepts of the model are described.  
 
                                                 
1
 Levine (1986) mentioned as possible risks of research for society for example: premature 
publication of research results that unnecessarily can cause panic or the opposite create hope (think 
about AIDS research). The escape of bacteria from a laboratory that possibly can cause an epidemic 
is another example.  
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Judgment and evaluation 
As mentioned above, a judging and evaluative process that consists of two 
parts, a primary appraisal and a secondary appraisal, will precede the coping 
(=decision making) in the theory of coping with stressful life events. The primary 
appraisal refers to the perception, judgment and evaluation of an event as stressful 
with respect to the well-being of the person; the secondary appraisal to the question 
whether something can be done to take away the threat. Both appraisals can be filled 
out with the three stages that are distinguished in the model of risk assessment, 
namely: (1) risk identification, (2) risk estimation, and (3) risk evaluation. As can 
been seen in Figure 2.1, in our conceptual model these stages not only refer to the 
risks – as in the risk-assessment approach – but also to the benefits. Determining the 
risks consists of the identification and estimation of the inconvenience, of the 
likelihood, severity, duration, reversibility and amenability to treatment of the 
physical risks (i.c. the toxicity), and of the likelihood, severity and duration of 
psychosocial risks (or distress). Determining the benefits consists of the 
identification and estimation of the likelihood, duration and importance of the 
benefits to the research subjects and of the importance of the research to future 
patients and medical science. The risk evaluation (and benefit evaluation) is done for 
the risks and the benefits separately as well as in relation to each other (weighing the 
risks and benefits), as can been seen in the two instances in Figure 2.1 where 
evaluation of risks and benefits takes place.  
 
Decision making 
Decision making itself consists of problem-focused and of the so-called 
emotion-focused strategies, as can be seen in Figure 2.1. The problem-focused 
strategies are for instance rational weighing of risks and benefits and information-
search processes. Emotion-focused strategies or emotion-regulation processes are 
strategies such as mental anticipation, denial or wishful thinking. These emotion-
regulation processes are distinguished in the theory of coping with stressful life 
events (Lazarus & Folkman, 1984, 1991) and in the theory of decision making under 
conflict or stress (Janis & Mann, 1977). We expected (part of) these latter processes 
also to take place when IRBs and IRB members need to assess the RBR of clinical 
cancer trials, especially when it is not easy to decide on the ratio between the risks 
and the benefits of the trial.  
Although approving or rejecting a research protocol is different from 
important individual decisions with consequences for a person’s life such as 
decisions to divorce, to have children or to change career (examples in the theory of 
decision making under stress), we do think that our conceptual model can contribute 
to the clarification of the RBR assessment by IRBs and IRB members. The main 
reason is that recent developments in the descriptive approach of decision making in 
cognitive psychology underline the importance of emotional factors on decision 
making in general (Koele & Van der Pligt, 1993; Harte & Koele, 1997). 
 
Determining factors 
The factors that influence decision making in the theory of interactive 
evaluation and decision making and in the descriptive approach of decision making 
are person-related and context-related factors, such as personal beliefs, problem-
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solving skills, social skills, social support, material resources, extent to which the 
threat is felt, motivational, cognitive and emotional factors, time-related factors, and 
factors that correlate with the complexity of the task. The factors present in the 
theoretical and empirical literature on the RBR assessment which we used to fill out 
the determining blocks in the model, will be mentioned below. More information 
about the relationship between these factors and the RBR assessment can be found 
in a separate review of the literature (Van Luijn, forthcoming).
2
 Research into the 
RBR assessment by IRB members and IRBs of research protocols is limited. 
Sometimes the literature is already quite old; often the research is qualitative with a 
limited number of respondents. This means that the literature is mainly used to 
develop an indicative conceptual model.  
The factors determining the RBR assessment by IRB members and IRBs of 
research protocols mentioned in the theoretical and empirical literature are: the 
identification, estimation and evaluation of risks and benefits to participating 
patients, future patients and medical science (Meslin, 1989, Levine, 1986, Shannon 
& Ockene, 1985) and person- and context-related factors. Person-related factors 
determining the decision making and RBR assessment are: the professional status 
and sociodemograhic characteristics of IRB members (Berghmans et al., 1996, 
1997), the competence of IRB members (Schwartz, 1983; Williams, 1984; Meslin, 
1989), (un)clarity about the risk/benefit ratio concept and about legal regulations or 
lack of rules (Levine, 1986; Meslin, 1989; Williams, 1984), IRB members' judgment 
about the relevance of scientific and risk/benefit issues for the RBR assessment 
(Berghmans et al. 1996, 1997), IRB members' focus on rights, rather than well-being 
of participating patients (Williams, 1984), and IRB members' beliefs on the value of 
life (Tiemstra, 1995). Context-related factors are: the available information in 
protocols (Meslin, 1989), available alternative treatments (Meslin, 1989), the 
composition of the IRB (Williams 1984; Meslin, 1990; Holm, 1992; Darvall, 1995; 
Berghmans et al., 1996), the quality of the researcher or the fact that the researcher 
is known, and the presence of researchers during committee meetings (Shannon & 
Ockene, 1985). In this chapter we do not describe how these factors are related to 
the RBR assessment by IRB members or IRBs of research protocols. This can be 
found in the review of the literature, as said earlier and also partly in the separate 
articles.  
                                                 
2
 Van Luijn, H.E.M. (2005). De bepaling van de risk benefit ratio van medisch experimenteel 
onderzoek door medisch-ethische toetsingscommissies. Een literatuuroverzicht. [The assessment of 
the risk benefit ratio of medical experimental research by Institutional Review Boards (will be 
published as a separate report).  
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Person-related factors 
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ment 
-IRB members’ focus on  
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of well-being 
-IRB members’ beliefs on 
‘the value of life’ 
 
 
 
 
Context-related factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Judgment, evaluation and decision making by IRB members on the 
risk/benefit ratio (RBR) assessment of Phase II and III cancer clinical trials 
 
 
This model is translated into the different instruments that were used in this 
study (semi-structured interviews, questionnaire, extended interviews and 
observation). The operationalization of the different blocks of the model can be 
found, as noted above, in the Method & Subjects sections of the articles. 
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3     Assessment of the risk/benefit ratio of phase II cancer 
clinical trials by Institutional Review Board (IRB) members 
* 
 
 
Summary 
           Background: This study examined the assessment of risk/benefit ratios for 
phase II cancer clinical trials by Institutional Review Board (IRB) members.  
Subjects and Methods: Semi-structured interviews were conducted with 53 members 
of IRBs from six research hospitals and specialized cancer centers in the 
Netherlands. Results: While the toxicity and side-effects of treatment were most 
often identified as risks associated with participating in a phase II trial, 
approximately two-thirds of IRB members also cited psychosocial and/or quality-of-
life risks. Conversely, 68% of the respondents identified psychosocial benefits of 
trial participation, while 25% cited treatment effectiveness as a possible benefit. 
Between one-quarter and two-thirds of respondents indicated that trial protocols 
provide insufficient information about the likelihood, magnitude and duration of 
both risks and benefits. Between 15% and 34% of IRB members reported feeling 
less than fully competent to evaluate various aspects of phase II protocols (e.g., 
originality and feasibility of the study, adequacy of the methods and analysis 
procedures, etc.). This was particularly the case for non-physician IRB members. 
Few IRB members reported weighing risks and benefits in a systematic manner, but 
rather relied on global impressions or preferred to leave such matters to the IRB as a 
whole or to their patients. 
Conclusions: A substantial minority of IRB members believes that trial protocols 
provide too little information relevant to evaluating various cost/benefit and 
scientific issues, and feels less than fully competent in carrying out such evaluations. 
IRB members are more likely to identify psychosocial benefits than physical health 
benefits that may accrue to patients participating in phase II trials.  
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3.1     Introduction 
 
Despite the importance of the work of Institutional Review Boards in 
the ethical conduct of human research, the process of decision-making by 
IRB members has been the subject of only limited study. (Cooke & 
Tannenbaum, 1977; Gilbert et al., 1989; Hall, 1991; Miller, 1989; While, 
1996; Goldman & Katz, 1982; Levine et al., 1984; Foster et al., 1995; Harries 
et al., 1994). While variability in both the process and outcome of decisions 
made by IRBs has been documented in the U.S. (Goldman & Katz, 1982) 
and elsewhere (Harries et al., 1994), there is a general consensus that the 
assessment of risk and benefit is an essential part of the protocol review 
process. A study of 11 IRBs in the Netherlands ranked risk/benefit ratio, 
scientific validity and the adequacy of patient information as the most 
important factors considered by IRB members (Berghmans et al., 1996). The 
authors of this study concluded that the protection of research subjects 
against excessively risky and/or burdensome research 
 
*     H.E.M. van Luijn, A.W. Musschenga, R.B. Keus, W.M. Robinson & N.K. Aaronson 
(2002). Annals of Oncology, 13 (8), 1307-1313.   
is taken very seriously by IRBs, but they did not describe the process of 
review used in evaluating trial protocols. Although most IRB members set 
great store by the risk/benefit ratio and scientific issues, they also find them 
difficult to evaluate (Berghmans et al., 1996; Bjune & Gedde-Dahl, 1993; 
Meslin, 1990; Meslin et al., 1994). This is especially true for non-medical IRB 
members (Berghmans et al., 1996). The assessment of the risk/benefit ratio 
and lack of consensus on the criteria IRBs use in their evaluations have 
been identified as weak links in the evaluation process (Meslin, 1993a,b). 
 
The study reported here is the first of a four-part investigation designed to 
gain greater insight into RBR assessments of phase II and phase III cancer clinical 
trials. This first stage of the research involved conducting semi-structured interviews 
with IRB members to determine their attitudes, beliefs and experiences in evaluating 
the RBR of phase II cancer clinical trials, in general (Van Luijn, 2000). In the 
second stage of the study, IRB members were asked to evaluate two protocols (a 
phase II and a phase III clinical trial) by means of a questionnaire. In the third stage, 
in-depth interviews were conducted with the IRB members about the protocol 
evaluations that they had carried out in stage two. The final stage of the study 
involved observation and analysis of the meetings of the full IRBs of two of the 
participating hospitals during which the two protocols evaluated in stages two/three 
were discussed. The results from the second through fourth stages of this 
investigation will be reported in subsequent papers.  
 
In the first stage of this research, we evaluated four aspects of the risk/benefit 
assessment process: (1) identification of the risks and benefits of phase II cancer 
clinical trial protocols, (2) estimation of the amount of information needed to make a 
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risk/benefit assessment and whether such information is typically available in phase 
II clinical trial protocols, (3) self-reported competence of IRB members to make 
risk/benefit assessments, and (4) evaluation of specific risks and benefits for patients 
participating in phase II clinical trials, for future cancer patients, and for medical 
science. 
 
 
3.2     Subjects and methods  
 
Study subjects  
IRB members from 6 hospitals in the Netherlands were invited to participate 
in the study, including the academic hospitals of the universities of Utrecht, 
Rotterdam, and Leiden, the Vrije Universiteit in Amsterdam, the Netherlands Cancer 
Institute/Antoni van Leeuwenhoek Hospital in Amsterdam, and the Daniel den Hoed 
Cancer Center in Rotterdam. Sixty-five IRB members were originally approached, 
of whom 53 (81%) agreed to participate. The remaining twelve individuals declined 
to participate due to the time-consuming nature of the research. The participating 
IRB members included medical specialists (41%), family physicians (8%), nurses 
(15%) and other disciplines (36%), including four pharmacists, two ethicists, two 
social scientists, one statistician, one attorney and others (17%). The age of the 
participants  
 
ranged from 28 to 69 years. The majority (64%) was male. Nine percent had been an 
IRB member for less than 1 year, 47% for 1-4 years, and 44% for 4 years or longer. 
 
Study measures – the semi-structured interview 
The semi-structured interviews, including a combination of open- and 
closed-ended questions, focused on the identification, estimation and evaluation of 
the risks and benefits associated with phase II clinical trials. On average, the 
interviews took approximately 1 hour to complete.  
 
Identification of risks and benefits 
A series of open-ended questions was asked about the identification of risks 
and benefits associated with phase II studies: (1) “How do you determine what risks 
and benefits to participating patients are associated with phase II studies?” (2) 
“What type of risks and benefits (to participating patients) do you identify in phase 
II studies? and (3) “What type of benefits do you identify in phase II studies for 
future patients and for medical science?” 
 
Estimation of risks and benefits 
Two types of questions with closed-ended response categories were asked 
about the estimation of risks and benefits associated with phase II studies: (1) on the 
adequacy of information contained in trial protocols for evaluating risk/benefit 
issues; and (2) on the perceived competence of IRB members to evaluate scientific 
and risk/benefit ratio issues. The adequacy of the information contained in trial 
protocols was assessed with the question: “In general, do you think that you are 
given enough information (empirical data) in phase II protocols to judge the 
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following issues?” Responses were scored on a 4-point Likert-type scale, ranging 
from ’more than enough’ to ‘very insufficient.’ The specific issues addressed are 
listed in Table 3.1.  
 
A modified version of a questionnaire developed at the Institute of Health Ethics in 
Maastricht (the Netherlands) was used to assess the perceived competence of IRB 
members in protocol evaluation. Respondents were asked: “In general, how easy or 
difficult do you find it to evaluate the following risk/benefit and scientific issues of 
phase II cancer clinical trial protocols? In other words, how competent do you feel to 
evaluate these issues?” The specific issues addressed are listed in Table 3.2. 
Response categories ranged on a 5-point Likert-type scale from ‘very easy’ to ‘very 
difficult’.  
 
 
 
 
 
 
 
 
 
 
 
Table 3.1: Perceived adequacy of information contained in phase II protocols  
(N=53) 
 
                                                                                           Percent rated as (very) insufficient 
 
The type of benefits to the patient      8% 
The likelihood of benefits to the patient     26% 
The magnitude of the benefits to the patient    36% 
The duration of the benefits to the patient    46% 
The type of risks to the patient      19% 
The likelihood of risks to the patient     44% 
The seriousness of the risks to the patient    36%  
The duration of the risks to the patient     60% 
The reversibility of the risks to the patient    36% 
The importance of the research for future patients   11% 
The importance of the research for science    10% 
 
 
 
Table 3.2: Perceived competence to evaluate risk/benefit and scientific issues of 
phase II protocols (N=53) 
                                                        
                                                                                                Percent rated as (very) difficult 
Risks/benefit issues 
The burden, inconvenience and risks to participating patients   30% 
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The toxicity and side-effects of treatments     23%  
The degree of invasiveness of the treatments      15%  
The benefits to participating patients      34% 
The benefits to future patients       34% 
The benefits to medical science       21% 
 
Scientific issues 
The aims of the trial         8% 
New insights provided by the trial       15% 
The originality of the trial       40% 
The feasibility of the trial       34% 
The scientific methodology of the trial      30% 
The scientific relevance of the study       6% 
The relationship of the trial to earlier studies     32% 
How the data are to be analyzed       42% 
  
 
 
 
 
 
 
 
Evaluation of risks and benefits 
Two related, open-ended questions were posed to determine how IRB 
members evaluate the risks and benefits of phase II clinical trials: (1) “How do you 
judge the acceptability of risks in relation to the benefits to participating patients, 
future patients and society? This was sometimes followed up with: “In other words, 
how do you weigh risks and benefits against each other?” and (2) “What is most 
often the decisive factor in your decision as to whether the benefits outweigh the 
risks involved?” 
 
Data Analysis 
Open-ended questions with respect to the identification and evaluation of 
risks and benefits were organized into categories and reported as percentages (see 
Tables 3.3 through 3.5). The resulting categories were not mutually exclusive 
because IRB members could mention more than one risk or benefit (Table 3.3), 
methods for evaluating risks and benefits (Table 3.4) or decisive factor (Table 3.5).  
Descriptive statistics were generated for the closed-ended questions with 
respect to the estimation of risks and benefits. The X2 statistic was used to test the 
relationship between professional status and length of IRB membership, on the one 
hand, and the risk/benefit estimation on the other. Specifically, we compared the 
closed-ended responses of: (1) physicians (n=26) versus other professionals (n=27), 
(2) oncologists (n=9) versus other IRB members (n=44), and (3) those with 1-4 
years experience as a member of an IRB (n=30) versus those with more than 4 years 
experience (n=23) with respect to: (a) the perceived adequacy of information 
typically available in phase II cancer protocols; and (b) the perceived competence to 
evaluate the scientific and risk/benefit ratio issues of those protocols. Results 
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pertaining to the identification and evaluation of risks and benefits were not 
submitted to subgroup analyses because the large number of categories derived from 
these qualitative data did not lend themselves to such comparisons. With respect to 
the identification of benefits to future patients and medical science, however, all 
respondents answered identical.  
 
 
3.3      Results 
 
Identification of risks and benefits 
Not surprisingly, several different approaches to identifying the risks and 
benefits to patients were reported, ranging from critical reading of protocols and/or 
patient information to using one’s own experience or consulting with experts and 
study coordinators for advice. Some IRB members reported focusing on the risks 
alone or on risks in relation to benefits, while others also consider the alternative 
treatment options for the patient group within and outside of the clinical trial 
protocol. 
Table 3.3 displays the types of risks and benefits to patients participating in 
phase II clinical trials identified by IRB members. All of the respondents identified 
the toxicity and side-effects of treatment, and nearly all the additional burden 
associated with trial participation (e.g., frequent visits to the hospital, extra tests) as 
common risks associated with trial participation. Less self-evident was that 65% of 
the respondents identified psychosocial risks associated with trial participation. 
These included uncertainty about what is going to happen, a potential (and false) 
sense of hope about treatment efficacy, and confrontation with the fact that the 
disease cannot be cured; that the treatment may be of only limited or no direct 
benefit. Additionally, 20% of the respondents reported a decrease in quality of life as 
a risk of treatment.  
Conversely, 68% of the respondents indicated a number of specific 
psychological benefits associated with participation in a phase II trial. These 
included an increase in the amount of attention and support received from medical 
and ancillary health care providers, a sense that there is still something that can be 
done to actively treat the disease, as well as a personal feeling of being able to “fight 
back” against the disease. Approximately one-third of the respondents identified 
improved quality of life as a potential benefit of trial participation. Approximately 
one-quarter of the IRB members interviewed identified treatment efficacy as a 
possible benefit. As expected, all respondents identified the potential for developing 
more effective cancer therapies as the primary benefit to future patients and to the 
scientific community.    
 
 
Table 3.3: Risks and benefits to phase II trial patients identified by IRB members 
(N=53) 
 
Type of risk 
Epected or unexpected side-effects and toxicity     100% 
(Frequency of) visits to and stays in hospital and extra tests   96%  
25 
 
Psychological and social risks       65% 
Decrease in quality of life       20%  
Various other factors        17% 
   
Type of benefit 
Possible treatment effect       24% 
Increase in quality of life       37% 
Psychological benefits        68% 
Various other factors         5% 
 
N.B. Percentages do not sum to 100% because respondents could mention more 
than one specific risk or benefit. 
 
 
 
Estimation of risks and benefits 
 
Perceived adequacy of information provided in protocols 
As indicated in Table 3.1, only a small minority of the respondents (8%) 
indicated that phase II protocols typically contain too little information about the 
types of benefits that might accrue to participating patients. However, between 
approximately one-quarter and one-half of the respondents reported that there is 
frequently insufficient information provided about the likelihood, the magnitude and 
the duration of such benefits.  
 
 
Similarly, most IRB members believed that protocols provide sufficient 
information about the types of risks involved in phase II clinical trials. However, a 
substantial percentage of the respondents indicated that too little information is 
available regarding the likelihood, seriousness, duration and reversibility of those 
risks (44%, 36%, 60% and 36%, respectively). Approximately 90% of the 
respondents indicated that sufficient information is provided regarding the potential 
importance of the clinical trial for future patients and for medical science.  
 
Perceived competence in protocol evaluation 
Between 15% and 34% of the IRB members reported that it was (very) 
difficult to judge the various risks and benefits associated with phase II clinical 
trials, both for participating patients and for future patients and society at large. 
While nearly all of the respondents indicated that they understood the aims (92%) 
and scientific relevance (94%) of phase II clinical trials, a substantial minority felt 
less than fully competent in evaluating the originality of the research (40%), the 
feasibility of the trial (34%), the scientific methodology employed (30%), the way in 
which the trial data were to be analyzed (42%), and how the trial relates to previous 
studies (32%).  
 
 
Evaluation of risks and benefits 
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Table 3.4 shows the different ways in which IRB members go about 
evaluating the risks and benefits of phase II studies. Most of the decision strategies 
followed do not reflect a process of weighing risks and benefits against each other in 
a systematic way, but rather involve gaining an overall impression (20%), 
considering what alternative treatments are available (15%), or considering whether 
one would be willing to undergo the trial-based treatment oneself or would advise a 
family member to do so (10%). Seventeen percent of the respondents indicated that 
they typically leave the decision as to whether the benefits of a trial outweigh the 
risks to the patients themselves, and 12% reported that it is a task for the IRB as a 
whole, rather than for himself or herself as an individual IRB member. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4: Methods used to evaluate risks and benefits of phase II protocols (N=53) 
 
Weighing risks and benefits systematically                             12% 
Global estimation based on impressions or feelings     20% 
Considering other treatment alternatives                              15% 
Considering whether one would participate oneself and/or  
advise a family member to do so                                                     10% 
Leave the evaluation to the patient                                            17% 
Leave the evaluation to the IRB as a whole 
Overall judgement of IRB as a whole       12% 
Various other methods         14% 
 
N.B. The figures do not sum to 100% because respondents could mention more than one factor 
 
 
The factors considered by IRB members to be decisive in assessing 
the risk/benefit ratio in phase II clinical trials are displayed in Table 3.5. 
Interestingly, one-third of the respondents were unable to identify such a 
factor in that they do not typically make such assessments themselves. The 
issue reported most frequently as being decisive was the potential value of 
the trial to future patients and to medical science (i.e., the potential of finding 
a more efficacious treatment) (21%). This was followed by the risks, burdens 
and inconvenience to participating patients (18%), the expectation that the 
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treatment would be beneficial to the participating patients (16%), and feeling 
comfortable in proposing the trial-based treatment to patients (11%).  
 
Table 3.5: Decisive factors in the assessment of the risk/benefit ratio of phase II 
protocols (N=53) 
 
Benefit to medical science       21% 
The risks, burden and inconvenience to patients     18% 
Reasonable expectation of benefit to the patient     16% 
Feeling comfortable proposing trial-based treatment to patients?   11% 
Would participate self or advise a family member to do so?       5% 
Overall judgement of IRB as a whole        7% 
Various other factors        14% 
I do not make a risk/benefit calculation      34% 
 
N.B. The figures do not sum to 100% because respondents could mention more than one factor 
 
 
 
Professional status, length of IRB membership and RBR assessment  
 
All respondents, regardless of professional background, identified the 
potential for developing better cancer therapies, with the resulting benefits to future 
patients and to medical science as possible benefits of phase II trials. Physicians and 
‘other professionals’ also did not differ significantly with respect to the perceived 
adequacy of information contained in phase II trial protocols. However, a 
significantly greater percentage of the IRB members who were physicians reported 
feeling competent in assessing the originality of the research (58% versus 22%, p < 
0.05), the methodology employed (62% versus 41%, p < 0.01), and whether the trial 
would yield new insights (77% versus 37%, p < 0.05) (data not shown in tabular 
form).  
When comparing oncology specialists (i.e., medical, radiation or surgical 
oncologists) with other IRB members (including family physicians), 
statistically significant differences were observed in: (1) the perceived 
adequacy of information provided in trial protocols about the likelihood of 
benefits (100% versus 68%, p < 0.05) and risks (89% versus 49%, p < 0.01) to 
patients, and (2) perceived competence in evaluating the toxicity of the 
treatment (100% vs. 50%, p < 0.05), the invasiveness of the treatment (100% 
versus 55%, p < 0.01), the originality of the trial (89% versus 30%, p < 0.05), 
and the place of the trial in relation to previous research (89% versus 34%, p < 
0.05) (data not shown in tabular form). 
Relatively new IRB members (i.e., those who had been members for 4 years 
or less) were more likely than members of longer standing to report that trial 
protocols contain insufficient information on the likelihood of benefits (40% vs. 9%; 
p < 0.05) and the type of risks (23% vs. 14%, p < 0.05) to patients. No statistically 
significant association was found between length of IRB membership and perceived 
competence to evaluate trial protocols (data not shown in tabular form). 
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3.4      Discussion 
 
The current study was undertaken to gain a greater understanding of a 
number of interrelated issues involved in the evaluation of the risks and benefits of 
phase II cancer trials by individual members of IRBs. First, we were interested in 
identifying the range of factors that IRB members take into consideration when 
evaluating the risk/benefit of such trials. Not unexpectedly, the toxicity and side-
effects of treatment were most often cited as risks associated with participating in a 
phase II trial. However, psychological and quality-of-life factors were also very 
frequently identified as both potential risks and benefits of trial participation. These 
findings are in line with those of previous surveys of IRB chairmen and clinical trial 
principal investigators (Kodish et al., 1992), and suggest an intriguing asymmetry 
between the potential benefits of trial participation as cited by IRB members and 
those identified by trial patients. That is, previous studies have found that patients 
enrolled in cancer clinical trials overwhelmingly cite hope of physical, rather than 
psychological benefit as the primary motivation for their participation (Daugherty et 
al., 1995; Schaeffer et al., 1996; Miller, 2000). Additionally, our findings suggest 
that IRB members generally find it acceptable that patients undergo considerable 
physical risks in exchange for primarily psychological and quality-of-life benefits 
for themselves, as well as potential clinical benefits for future patients and medical 
science.   
Second, we investigated the perceived adequacy of the information typically 
available in phase II protocols, and the perceived competence of IRB members to 
make risk/benefit assessments. Although the large majority of IRB members 
indicated that trial protocols contain sufficient information about the types of risks 
and benefits involved in phase II trials in general, a substantial percentage (between 
approximately 25% and 60%) reported that too little information is available about 
more specific issues such as the likelihood, magnitude, and duration of such risks 
and benefits. This does not necessarily mean that phase II clinical trial protocols are 
poorly written. In some cases, it may not be possible to estimate accurately the exact 
nature of the risks and benefits involved. Nevertheless, the lack of detail provided in 
protocols may explain, at least in part, the finding that approximately one-third of 
IRB members do not make a risk-benefit calculation at all, and that 17% leave such 
matters up to the patients. This latter finding is somewhat disconcerting in light of 
the evidence that patients are often unable to fully understand the information 
provided to them about the clinical trials in which they are invited to participate 
(Daugherty et al., 1995; Schaeffer et al, 1996; Aaronson et al, 1996). 
A substantial minority of IRB members (ranging from 15% to 40%) reported 
feeling less than fully competent to evaluate the risks and benefits associated with 
phase II trials and the scientific details of phase II trial protocols. While these 
findings may give cause for concern, they need to be tempered by the fact that 
protocol evaluation is typically a multidisciplinary, group process. It may not be 
realistic or necessarily efficient to expect that every individual member of an IRB is 
capable of evaluating all aspects of a clinical trial. Additionally, although not 
typically the case in the Netherlands, some hospitals have separate committees for 
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evaluating the scientific versus ethical/human subject protection aspects of clinical 
trial protocols.  
Third, we inquired into the methods employed by IRB members to arrive at a 
risk/benefit estimate, and the most important factors taken into consideration in such 
estimates. Only a small minority of the respondents indicated that they weighed risks 
and benefits against one another in a systematic way. More typically, such 
evaluations are made at a more global level, based on both individual judgments 
regarding the acceptability of the trial, whether one would participate oneself, and 
on the results of the decision-making process of the IRB as a whole. It is unclear as 
to whether a more formal and systematic form of individual risk-benefit evaluation 
would yield different decisions. It might, however, foster greater clarity in the 
criteria used to reach decisions, and greater consistency in the application of such 
criteria across IRBs.  
Finally, we investigated whether there are systematic differences in risk-
benefit assessment as a function of the professional background and number of years 
of committee experience of IRB members. As might be expected, physicians 
(particularly those specialized in oncology) and IRB members of longer standing 
were less likely than other IRB members to report inadequacies in the information 
provided by phase II trial protocols, and indicated having less difficulty in 
evaluating the various scientific aspects of those protocols. Similar results have been 
reported in studies of IRBs, in general (i.e., not specifically focused on cancer 
clinical trials) (Berghmans et al., 1996, 1997).  
 
The current results need to be interpreted in the light of certain study 
limitations. First, we did not distinguish between different types of phase II 
protocols (e.g., chemotherapy, radiotherapy or surgery). While we have no reason to 
believe that this would have a significant impact on the findings, it is something that 
merits further study.  
Second, as noted above, the focus of our research was on the individual 
members of IRBs. The decisions made by IRBs, and the discussions that form the 
basis of such decisions, are of a collective nature. Each IRB member contributes to 
the decision-making process from his or her professional perspective and, 
undoubtedly, the whole is more than the sum of its parts. Thus, a more dynamic, 
group-oriented research approach is needed to obtain a comprehensive picture of 
both the process and content of risk-benefit assessment. Hopefully, the fourth phase 
of our investigation, in which we observed and analyzed the meetings of several 
IRBs, will shed additional light on the decision-making process, and the role of 
individual members in that process.  
Third, our study was restricted to members of IRBs from Dutch academic 
hospitals and specialized cancer treatment centers. IRBs in various European 
countries and in North America may differ in some respects (e.g., with regard to 
informed consent requirements, the need for hospitals and physicians to protect 
themselves against potential legal risks, etc.). Nevertheless, the basic structure, 
objectives and procedures for protocol review are quite similar across countries, and 
thus we believe that our results can reasonably be extended to other national systems 
of research oversight. Nevertheless, this needs to be confirmed empirically.  
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In summary, the results of this study indicate that there is a good deal of 
variability in the ways in which individual members of IRBs identify, estimate and 
evaluate the risks and benefits associated with phase II clinical trials in oncology. A 
substantial minority of IRB members believes that trial protocols provide too little 
information relevant to evaluating various cost/benefit and scientific issues, and 
feels less than fully competent in carrying out such evaluations. In general, IRB 
members are more likely to identify psychosocial benefits than physical health 
benefits that may accrue to patients participating in phase II trials. They view such 
trials primarily as a vehicle for testing new therapies that may be of benefit to future 
patients and to medical science, in general. While this is in line with the goals and 
objectives of the vast majority of phase II trials, it may not reflect the expectations 
of patients themselves, who often choose to participate in such trials in the hope that 
the treatment will prove to be clinically effective. This underscores the need to 
provide potential phase II clinical trial patients with sufficient information to make 
informed decisions, and to ensure that such decisions are appropriately motivated.  
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4     The evaluation of phase II and III cancer clinical trials 
by Institutional Review Board (IRB) members * 
 
 
Summary 
Background: This study examined the opinions of Institutional Review 
Board (IRB) members about the assessment of the risk-benefit ratio (RBR) of phase 
II and III cancer clinical trials.  
Methods: Semi-structured interviews were conducted with 53 members of IRBs 
from 4 academic hospitals and 2 specialized cancer centers in the Netherlands.  
Results: Lack of evaluation criteria, uncertainty concerning the benefits to patients, 
and insufficient information about the study rationale were mentioned most 
frequently as difficult aspects in RBR assessments of phase II and III cancer 
protocols. Fifty-six percent of the IRB members indicated that they could benefit 
from additional information and education in making risk-benefit assessments of 
such protocols. A similar percentage believed that more insight into the experiences 
of the patients involved in such trials, and their perceptions of the associated risks 
and benefits, could be useful to them in making RBR assessments. Forty-eight 
percent of the IRB members supported the inclusion of lay individuals in IRBs, but 
only 23% believed that it would be appropriate to include patients.  
Conclusions: More than half of the IRB members expressed interest in obtaining 
more information and education in making RBR assessments for phase II and III 
cancer protocols. Many also believed that better insight into the patients’ perspective 
could aid them in making such assessments. However, only a minority of IRB 
members would favor including patients on IRBs.   
 
 
4.1     Introduction 
 
The Declaration of Helsinki and other national and international 
regulations oblige Institutional Review Boards (IRBs) to weigh the risks of 
medical research against its benefits, and to assess the ratio between the 
two. In order for a study to be approved, this risk-benefit ratio (RBR) must be 
“favorable,” “in balance,” or “proportional” in the IRB’s opinion. IRBs have the 
responsibility of protecting research participants against studies that carry 
with them too many risks. This assumes that IRBs are sufficiently aware of 
which risks the medical research community and society, in general, find 
acceptable in relation to which benefits. The extent to which this assumption 
is justified in practice is open to question, especially considering the vague 
description of this requirement in the  
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various regulations. The requirement further presupposes that IRBs (and 
IRB members) know what trial participants find important with respect to their 
protection. Whether this assumption is justified is also unknown.   
 
The absence of clear criteria has been identified as a weak link in the 
IRB evaluation process (Meslin, 1993a,b). Previous studies have indicated 
that  
IRB members find RBR assessments to be one of the most difficult tasks 
involved in reviewing protocols (Berghmans et al., 1996; Goldman & Katz, 
1982; Levine & Katz, 1984; Gilbert et al., 1989; Miller, 1989; Meslin, 1990; 
Hall, 1991; Meslin, 1993a,b; Bjune & Gedde-Dahl, 1993; Harries et al., 1994; 
Foster et al., 1995; Berghmans et al., 1996; While, 1996). Little is known, 
however, about the kinds of difficulties IRB members experience when 
making RBR assessments, and whether the members need assistance in 
making these assessments. Whether IRB members find it desirable to have 
lay individuals and patients participating in IRBs with respect to RBR 
assessments is also unknown. In a previous study, we found that a 
substantial minority of IRB members believed that phase II cancer clinical 
trial protocols provide too little information relating to the evaluation of 
various cost-benefit and scientific issues, and felt less than fully competent in 
carrying out such evaluations (Van Luijn, 2000; Van Luijn et al. 2002). The 
study also revealed that only a small minority of IRB members weigh risks 
and benefits against one another in a systematic way, rather than intuitively. 
More typically, risk-benefit evaluations are made on a more global level, 
based on both individual judgments regarding the acceptability of the trial, 
and on the results of the IRB decision-making process as a whole. Finally, 
approximately one-third of IRB members did not determine the RBR ratio 
themselves, but rather preferred to leave that to the individual patients.  
 
 In the current paper, we report on a study that sought to determine which 
aspects of the RBR assessment of phase II and phase III cancer clinical trials 
individual IRB members find the most difficult, whether they require more 
information and education in making such assessments, how the process can be 
improved, and whether the participation of lay individuals and patients is viewed as 
a means of improving the quality of the assessments.
3
  
 
 
 
 
 
                                                 
3
 Phase II and III cancer clinical trials both study questions of therapeutic effect. 
Phase II trials, typically involving a limited number of patients, and addresses the 
question of whether a new therapeutic agent or treatment has an anti-tumor effect. 
Phase III clinical trials are typically larger in size, and randomize patients between a 
standard and an experimental treatment.  
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4.2     Patients and methods 
 
Study subjects  
Members of the IRBs of six hospitals in the Netherlands were invited to 
participate in the study, including the academic hospitals of the universities of 
Utrecht, Rotterdam, and Leiden, the Vrije Universiteit in Amsterdam, the 
Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital in Amsterdam, and 
the Daniel den Hoed Cancer Center in Rotterdam. Sixty-five IRB members were 
approached, of whom 53 (81%) agreed to participate. The remaining twelve 
individuals declined to participate due to the time-consuming nature of the research. 
The participating IRB members included medical specialists (41%), family 
physicians (8%), nurses (15%), and other disciplines (36%), including four 
pharmacists, two ethicists, two social scientists, one statistician, and one attorney, 
among others. The age of the participants ranged from 28 to 69 years. The majority 
(64%) was male. Nine percent had served on the IRB for less than one year, 47% for 
between one and four years, and 44% for four years or longer. 
 
Study measures: the semi-structured interview 
Semi-structured interviews, including a combination of open- and closed-
ended questions, focused on the most difficult aspects in assessing the RBR of phase 
II and phase III cancer clinical trial protocols, the perceived need for additional 
information and education in making RBR assessments, suggestions for improving 
these assessments, and the desirability of having lay individuals and patients 
participate in IRBs. On average, the interview took approximately one hour to 
complete.  
 
Risk-benefit assessments of phase II and III cancer protocols 
The interviews included two open-ended questions concerning the most 
difficult aspects of assessing the risks and benefits of phase II and phase III 
cancer protocols. One closed-ended question concerned the difference between 
RBR assessments of phase II and III cancer trials and other medical research: 
“Is it easier or more difficult for you to evaluate phase II and III cancer 
protocols than it is to evaluate other protocols on risk-benefit and scientific 
issues, or do you see no difference?”  
 
Need for more information and education in the RBR assessment process and 
suggestions for improving these assessments 
The interviews included three open-ended questions concerning the need 
for more information and education, and suggestions for improving the risk-
benefit assessment process for phase II and III cancer protocols:  
1. “Do you need more information and education in assessing the RBR 
of protocols?”  
2. “What kind of information and education do you need?”  
3. “Do you have any suggestions that would make the RBR assessment 
process easier for you?”  
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Desirability of having lay individuals and patients participate in IRBs 
“Two closed-ended questions concerned the desirability of having lay 
individuals and patients participate in IRBs:  
1. “Do you believe that it is desirable for lay individuals (other than 
patients)  to participate in an IRB?”  
2. “Do you believe that it is desirable for patients (e.g., potential trial 
participants) to participate in an IRB?”  
  Responses were scored on a 4-point Likert scale from 1 (very desirable) to 4 
(not desirable at all). Respondents were asked to describe the reasons underlying the 
responses that they provided to these questions.  
 
 
Data analysis 
Open-ended questions concerning the most difficult aspects of assessing the 
RBR for phase II and III cancer protocols, the type of support needed to make RBR 
assessments, and suggestions for improving these assessments were organized into 
categories and are reported as percentages. The resulting categories were not 
mutually exclusive, as respondents could mention more than one difficult aspect of 
RBR assessment (Table 4.1), type of support needed (Table 4.2), or suggestion for 
improving RBR assessments (Table 4.3). Responses are illustrated in the text with 
salient statements made by IRB members.  
Descriptive statistics were calculated for responses to the closed-ended 
questions concerning the risk-benefit assessment of oncology protocols (as 
compared to other protocols) and the desirability of having lay individuals and 
patients participate in IRBs. Chi-square statistics were used to test whether the 
background characteristics of the IRB members (e.g., age, gender, professional 
background, years of experience on IRBs) were associated significantly with 
perceived need for information and training, and attitudes towards lay and patient 
membership on an IRB.  
 
 
4.3     Results 
 
Assessing the risk-benefit ratio of phase II and III cancer clinical trials 
 
As reported in Table 4.1, making RBR decisions without clear criteria and in 
the face of uncertainty with regard to patient benefits and study rationale were 
perceived as the two most difficult aspects of the RBR assessment process for phase 
II and III cancer trials. Specific issues mentioned by respondents during the 
interview included the difficulty in comparing risks with benefits, inadequate 
knowledge of the acceptability of certain risks, and an inability to imagine the 
impact of a failed clinical trial-based treatment on patients’ lives. Some respondents 
reported that they try to imagine whether they would want to participate themselves, 
but found this to be difficult. Still others indicated that they, while they often would 
not want to participate themselves or advise  
Table 4.1: Opinions of IRB members concerning the most difficult aspects of 
assessing the RBRs of Phase II and Phase III cancer trials (N=53) 
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              Phase II     Phase III 
 
Lack of criteria to assess the RBR    62%  39% 
Uncertainty about the benefits to patients and  
the study rationale                                                  41%  37% 
Doing research/confronting patients with difficult  
choices in the face of necessary risks                                     15%    0% 
Gaining a view of all relevant factors               12%    2% 
Withholding treatment because of placebo     0%             10%   
Various other aspects                 21%
a 
            27%
b
 
 
a
 e.g. No feedback on study results, therefore it remains unclear whether the estimation and evaluation 
of risks and benefits was correct; communication with other IRB members about the RBR; the 
researchers’ reaction if the protocol is rejected. 
b
 e.g. No feedback on study results; uncertainty about toxicity; the perhaps unrealistic hope that is 
provided to patients by letting them participate in the study. 
 
N.B. The percentages do not total 100% because more than one response could be given. 
 
 
their loved ones to do so, this was not something that they could easily factor into 
their RBR assessment. Statements made by several of the respondents illustrated 
nicely some of the major difficulties experienced by IRB members in evaluating the 
RBR of trials:  
 
“The most difficult part is that you cannot really imagine the patient’s 
position. How does it feel to have cancer? You cannot know that unless you 
have cancer yourself. Your standards for quality of life change at that point. I 
often hear IRB members say, ‘I would never take part in this study myself, 
but the patients really want to participate” (Statistician).  
 
“The problem is that there are major uncertainties about the chance of risks 
and the chance of benefits, and that you are expected to compare apples with 
oranges. Risks and benefits are not given in comparable parameters. How do 
you weigh pain and hair loss against living a few months longer?” (Surgeon). 
 
“The most difficult aspect is imagining what a patient will go through in such 
a study. I know that, in general, the benefits of Phase II studies are minimal 
for both the participants and for medical science. They’re just selling hope” 
(Family physician). 
 
 
Sixty percent of the IRB members from the 4 academic hospitals (where clinical 
trials from a wide range of medical fields are reviewed), reported experiencing no 
differences in evaluating the RBR of oncology versus other types of protocols, 38% 
reported more difficulty in evaluating cancer protocols, and 2% found other types of 
protocols more difficult to evaluate.  
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Need for more information and education in assessing the risk-benefit ratio of phase 
II and III cancer clinical trial protocols 
 
Fifty-six percent of the IRB members reported that they would like to 
receive more information about and education in assessing the RBR of 
protocols. As indicated in Table 4.2, approximately half of those respondents 
who expressed interest in receiving more information or training favored 
courses or seminars, and one-third indicated a desire to obtain feedback on 
trial results and on the experiences of patients who participate in trials. 
Several direct quotes serve to illustrate this:  
 
 “More guidance would be useful. You can learn a lot from feedback 
concerning the results of phase II and III studies. It is important that 
the IRB be provided with a feedback system” (Pharmacologist).  
 
“To ask a large group of patients how they have experienced the trial 
and how they look back upon their participation. I think this will be 
very important to me with respect to the evaluation of protocols” 
(Nurse). 
 
The remaining 44% of the IRB members expressed no additional need for 
assistance in the RBR assessment of protocols, as they felt that the IRB 
meetings themselves provided sufficient training opportunities and sources 
of information.  
 
 
Table 4.2: Type of information and education desired by IRB members in assessing 
the RBR of phase II and III cancer clinical trials (N=30) 
a 
Courses or seminars      52%    
Feedback on patients’ trial experiences and trial results 32% 
Reflection on past decisions/overview  
of new developments in oncological research    8% 
Various 
b
       36% 
 
a
  Only IRB members who said that they needed more knowledge and education answered this 
question. 
b
 Including: RBR assessment by researchers; methodological aspects; how to apply general 
ethical concepts to particular protocols; guidelines about how to assess the RBR; feedback 
on individual IRB performance; more training in legal matters and animal research; a list 
with important things to think about for every member.  
N.B. The percentages do not total 100% because more than one response could be provided.  
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Suggestions for improving RBR assessment of Phase II and III cancer 
protocols 
 
As shown in Table 4.3, more than half of the IRB members reported 
wanting more information, particularly relating to the experiences of patients 
with clinical trials and their perceptions of the risks and benefits involved. As 
one family physician put it:  
 
 “It is very important to know how patients experience trials. A lot is taken 
for granted. Oncologists often believe that patients always are searching for 
hope. It is debatable, however, whether this is true. In general, IRBs assume 
that patients want hope and thus choose to be treated. I would like other IRB 
members to receive more training with regard to what patients experience, 
and I would like to know more about the medical and oncological aspects.”  
 
Approximately one quarter of the respondents reported that it would be 
helpful if investigators themselves were to include their own RBR assessments as 
part of the trial protocol. Additional training and the use of a checklist in order to 
review all of the major issues involved in RBR assessments were also mentioned as 
possibly helpful in facilitating the review process. Other suggestions included 
providing more feedback on trial results, ensuring that a broader range of disciplines 
representing the patients’ perspective is represented on IRBs, having access to a 
database containing the results of earlier studies, and encouraging more critical 
discussions between IRB representatives and researchers prior to or during IRB-
meetings. 
 
 
Table 4.3: IRB members’ suggestions for improving the risk-benefit assessment 
of Phase II and III cancer clinical trials (N=53) 
a 
 
More knowledge available on trial experience/ 
risk-benefit perceptions of patients    56% 
RBR assessments by researchers    26% 
Additional training and checklists for IRB members  23% 
More time for preparation and discussion/ 
contact with researchers                                                           9% 
Improvement of IRB discussions      7% 
Various                  28% 
 
a 
The percentages do not total 100% because more than one suggestion could be given.  
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Membership of lay individuals and patients in the IRB  
 
Forty-eight percent of IRB members were in favor of having lay members 
serve on IRBs (Table 4.4). They believe that lay individuals can offer fresh 
perspectives, are focused more on the psychosocial consequences of trial-
participation, and can form a counterweight to the other members who are 
typically involved themselves in doing research.  
Of the remaining respondents, 44% were opposed to having lay 
individuals as IRB members, and 8% had no opinion on the matter. The primary 
reasons for opposing lay members were: (1) a belief that lay individuals would 
not make any substantial contribution; (2) concern that the task would be too 
difficult for lay individuals; and  
(3) a belief that the lay perspective was already sufficiently represented (e.g., via 
nurses).  
The majority of respondents (54%) opposed the idea of having patients 
participate on the IRB. Those who rejected this proposal did not believe that 
patients had any specific contribution to make, were concerned that open 
discussions would be hampered, believed patients would make judgments solely 
on the basis of their own, personal experiences, or felt that participation on an 
IRB would simply be too difficult or would impose too great a burden on 
patients. Still others believed that the logistics would be difficult because 
different patients would be needed for different protocols, or that it would be 
difficult to find a single patient who could represent the diverse population(s) of 
patients.  
Twenty-three percent of the IRB members considered it desirable to have 
patients on IRBs, and the remaining 23% expressed no opinion. Most of those 
favoring patient participation considered patients to be “experiential experts” 
who could inform other IRB members about the meaning of risks and benefits. 
Others believed that patients are better able to evaluate the quality of written 
patient information than other IRB members.  
 
 
Table 4.4: IRB members’ opinions about the desirability of having lay individuals 
and patients participate in IRBs (N=53) 
 
 
Lay participation on IRBs is desirable    48% 
Lay participation on IRBs is not desirable    44% 
Don’t know/no opinion        8% 
 
Patient participation on IRBs is desirable    23% 
Patient participation on IRBs is not desirable   54% 
Don’t know/no opinion      23% 
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The effect of IRB members’ background characteristics  
 
Physicians did not differ significantly from other professionals in their 
opinions about the need for more information and education in making risk-benefit 
assessments of phase II and III cancer protocols. This was also the case for nurses 
compared to other professionals. However, significantly fewer oncologists believed 
that they could benefit from more information and education than did other 
professionals (18% versus 62%; p < .05). No statistically significant associations 
were found between duration of IRB membership, age or gender and the perceived 
need for more information and education.  
A significantly larger percentage of younger IRB members (age < 40) 
favored lay participation in IRBs than did older members (70% versus 38%; p =. 
05). No other background variables were related significantly to opinions regarding 
lay membership.  
Relatively new IRB members (those with four or fewer years of experience) 
were significantly more likely to favor patient participation on IRBs than were 
members with more experience (38% versus 4%; p=.02). Although not statistically 
significant, fewer physicians than other professionals favored having patients as 
members of IRBs (12% versus 35%).Finally, female IRB members rejected the idea 
of patient IRB participation significantly more often than did their male counterparts 
(72% versus 44%; p = .02).  
 
   
4.4     Discussion 
 
The objective of this study was to provide greater insight into the RBR 
assessment process for phase II and III cancer clinical trials as experienced by 
individual members of IRBs. We first sought to identify the most difficult aspects of 
the RBR assessment of phase II and III protocols. The lack of RBR assessment 
criteria, and uncertainty concerning the benefits to patients and the study rationale 
were reported as the most difficult aspects of the process. Other studies have also 
found a lack of clear criteria for evaluating the RBR assessment and board members’ 
lack of technical expertise necessary for weighing the risks and benefits against each 
other to be major problems (Meslin, 1989; Meslin et al. 1994; Churchill et al. 2003).  
In our previous study we found that one-third of IRB members could not 
report a decisive factor in their assessment of the RBR of Phase II cancer protocols, 
because they did not determine this ratio themselves, but left it to the patients (Van 
Luijn, 2000; Van Luijn et al., 2002). It is not unthinkable that lack of decision-
making criteria and uncertainty concerning both the benefits to patients and the 
study rationale, could explain why many IRB members apparently prefer not to 
evaluate the RBR of such protocols.  
We were also interested in determining whether Phase II and III cancer trials 
were considered more difficult to evaluate than were other medical research 
protocols. The majority of IRB members experienced no differences in this regard. 
This suggests that our findings on the RBR assessments of cancer protocols may 
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also apply to the evaluation of medical research, in general. This is, of course, 
something that would need to be confirmed empirically. 
 
Second, we investigated the needs expressed by IRB members for more 
information and education in assessing the RBR of phase II and III cancer protocols 
and their suggestions for improving their assessments. Almost two-thirds of the 
respondents reported that additional information and education would be welcome. 
Most expressed a desire to attend courses or seminars or to receive feedback 
concerning the trial experiences of patients, as well as results from the trials. 
Although courses are available for IRB members in the Netherlands, they are not 
mandatory and only a small percentage of members attend them.   
The IRB members made a number of suggestions regarding possible ways to 
improve RBR assessments of phase II and III cancer protocols. Most indicated that 
they would like to receive more information about patients’ trial experiences and 
risk-benefit perceptions. In addition, the availability of RBR assessments made by 
researchers themselves, checklists for IRB members, and more training facilities 
were mentioned as ways of improving RBR assessments. In particular, these 
findings indicate that knowledge is currently lacking concerning the perceptions and 
experiences of patients. In addition, the findings suggest a striking tension in IRB 
members’ apparent lack of insight into the patient perspective (i.e. the meaning of 
the risks and benefits to patients) and their actual task (protecting human subjects 
against medical research that carries too many risks). Fifty-six percent of IRB 
members believed that more knowledge about patients’ experiences with and 
perceptions of these issues could improve their RBR assessments. This also suggests 
that, to be capable of assessing the RBR (i.e. to have criteria for weighing risks and 
benefits against each other), more knowledge of the patients’ perspective is needed.  
To determine whether their decisions are ethically justifiable, IRB members 
must imagine the consequences of their decisions for patients (Martin et al., 1995). It 
is impossible, however, to know how others will actually assess these consequences; 
an IRB member can make only a rough guess of what their decisions will mean to 
others (Martin et al. 1995). Risk-benefit assessments depend on the relative 
importance of the different factors to be weighed. More insight is needed, therefore, 
into the values and goals of patients, if IRBs are to be capable of determining their 
importance, and if risk-benefit criteria are to be well chosen (Ackerman, 1995).  
 
Third, we asked IRB members their opinions about the desirability of having 
lay individuals and patients participate in IRBs. Lay members are relatively common 
in IRBs in the U.S. and in some European countries (also in several IRBs in the 
Netherlands), Results of a Danish study indicated that lay members are capable of 
signaling inadequate risk-benefit assessments and often made the most useful 
comments about ambiguities in the consent forms (Holm, 1992). Others have 
emphasized the importance of lay individuals’ uniquely informed estimations of the 
severity and importance of risks and benefits for IRB review (Reinders, unpublished 
paper). Experiences with patients reviewing AIDS protocols have been positive (Till 
et al., 1992), and patients estimate the severity of certain risks in a manner that 
differs considerably from that of physicians and nurses (Slevin et al. 1990). 
Nevertheless, although the respondents in the current study indicated that more 
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insight into the patients’ perspective could facilitate their making RBR assessments, 
less than half were in favor of having lay members of IRBs.  
 
Finally, we studied the effect of background characteristics on IRB 
members’ ratings. Not surprisingly, we found that fewer oncologists felt the need for 
more information and education in making RBR assessments than did other 
professionals. Female IRB members and those who had been involved in IRBs for a 
longer period of time tended to be less favorable toward having patients participate 
in IRBs. Also, older members tended to be less supportive of having lay individuals 
on IRBs. It may be that older members and members with a longer association with 
an IRB believe that their experience provides them with sufficient insight into the 
protocol review process, or they may simply have more conservative views about 
who should be represented in IRBs. Why fewer female IRB members are in favor of 
having patients participate is unclear. Although most nurses in this study were 
female, there were also many females from other professions, and being a nurse had 
no significant relationship with attitudes towards patient participation. 
 
The current results must be interpreted in light of certain limitations of the 
study. First, the study did not distinguish among the various types of phase II and III 
protocols (e.g. chemotherapy, radiotherapy, or surgery). While there is no reason to 
believe that this would have a significant impact on the findings, the issue does merit 
further study. In addition, respondents were not asked to distinguish between 
protocols arising from within their own institutions and those from other sources 
(either national or international). Attempts to obtain systematic data on this matter 
from the participating IRBs proved unsuccessful, because such information is not 
routinely registered in databases and is thus not readily accessible. Additional 
research is needed, therefore, to determine whether the perceptions of difficulties 
associated with assessing the RBR of protocols and the need for information and 
education vary significantly according to their source (e.g. local versus national or 
international; academic versus industry). 
As a second cautionary note, the focus of our research was on the individual 
members of IRBs. The decisions made by IRBs as a whole, and the discussions that 
form the basis of such decisions, are of a collective nature. Each IRB member 
contributes to the decision-making process from a unique professional perspective, 
and the whole is undoubtedly more than the sum of its parts. A more dynamic, 
group-oriented research approach is also needed, therefore, to obtain a 
comprehensive picture of the issues surrounding risk-benefit assessments.  
 
In summary, part of the results of this study indicate an intriguing paradox. 
On the one hand, a lack of criteria and uncertainty about the benefits to patients and 
the rationale of the study make RBR assessments of phase II and III cancer trials 
difficult, most IRB members would like to receive additional information and 
education in assessing the RBR of such trials, and most believe that additional 
insight into the experiences and perceptions of patients would help improve the 
assessment process. On the other hand, for about half of the Dutch IRB members, 
having patients participate on IRBs appeared to be an unworkable solution to this 
lack of familiarity with the patients’ perspective. We therefore conclude that – 
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beyond the availability of RBR assessments made by researchers themselves, 
checklists for IRB members, and more training facilities (also often mentioned 
suggestions by IRB members for improvements of RBR assessments) - more 
empirical research is needed into the trial experiences and perceptions of patients. 
There are some indications that patients’ experiences of recruitment to early cancer 
trials and their perceptions of the informed consent process, reflect a lack of 
understanding of what they were taking part in, and that the psychological, 
emotional and social impact of taking part in clinical trials is better uncovered by in-
depth interviews than by standardized quality of life questionnaires (Daugherty, 
1999; Joffe et al, 2001; Cox, 2002; Cox, 2003). Additionally, studies are needed to 
investigate the effects, both positive and negative, of having lay individuals or 
patients participating in IRBs. Both lines of research would be promising first steps 
toward improving the RBR assessments of Phase II and III cancer clinical trials by 
IRB members.  
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5     The evaluation of the risks and benefits of phase II cancer 
clinical trials by Institutional Review Boards (IRB) members: 
A case study *  
 
 
Summary 
Objectives: There are indications that IRB members do not find it easy to 
assess the ratio of the risks to the benefits in medical experiments, although this is a 
principal duty of Institutional Review Boards (IRBs). This study examined how 
Institutional Review Board (IRB) members assessed the risk/benefit ratio of a 
specific Phase II breast cancer clinical trial. 
Subjects and methods: The Phase II breast cancer clinical trial was evaluated by 
means of a questionnaire administered to 43 members from IRBs at six research 
hospitals and specialized cancer centers in the Netherlands. The following topics 
were addressed in the questionnaire: (1) the identification and estimation of the 
inconvenience, toxicity, psychosocial distress, and the benefits of trial participation 
to patients, (2) the identification and estimation of benefits to future patients and 
medical science, (3) the evaluation of the importance of specific risks and benefits in 
the risk/benefit ratio of the trial, (4) the assessment of the risk/benefit ratio of the 
study, and (5) the assessment of the ethical acceptability of the study.  
Results: (1) Most IRB members expected trial participation to carry with it fairly or 
very serious inconveniences, fairly severe to sometimes life-threatening toxicity, and 
serious psychological and social consequences. Conversely, the perceived likelihood 
of benefits to patients was modest. (2) Most regarded the study to be important, the 
ratio between risks and benefits to be favorable, and believed that the protocol 
should be approved. Significant relationships were found between several specific 
risks and the overall RBR assessment. Of the benefits, the duration of tumor 
remission and symptom-free survival, and the perceived importance of tumor 
remission were related significantly to the assessment of the overall RBR and to the 
ethical acceptability of the trial. (3) There was a significant relationship between the 
assessment of the RBR and of the ethical acceptability of the trial. (4) If corrected 
for other IRB characteristics, only gender was significant with respect to the 
evaluation of the ethical acceptability of the trial.  
Conclusions: (1) Most IRB members felt competent to estimate specific aspects of 
the risks and benefits such as likelihood and severity, to determine the RBR, and to 
assess the ethical acceptability of the trial. (2) Although IRB members state that they 
do attach a heavy weight to the risks, their final judgment on the trial’s ethical 
acceptability is only significantly correlated to the benefits of the duration of 
remission and symptom free survival and not to the risks or the other studied 
benefits to participating patients.  
 
*     H.E.M. van Luijn, N.K. Aaronson, R.B. Keus, & A.W. Musschenga. Submitted to The Journal 
of Medical Ethics
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5.1     Introduction 
 
There are indications that institutional review board (IRB) members do not 
find it easy to assess the ratio of the risks to the benefits in medical experiments, 
although this is one of their principal duties (Meslin, 1989; Meslin, 1993a,b; 
Berghmans et al., 1996, 1997). Not only do IRB members have difficulty identifying 
the relevant risks and benefits of a particular protocol, they also find it difficult to 
compare those risks and benefits because (1) the nature, extent and the duration of 
risks and benefits are often uncertain, (2) the nature of the various risks and benefits 
is very diverse, and (3) all of the risks accrue to the research subjects, while some of 
the benefits accrue to future patients and/or to medical science.  
IRBs are legally required to evaluate whether the risk/benefit ratio (RBR) is 
‘reasonable’, ‘proportional’ or ‘favorable’. Since there is no consensus on the 
content of, and categories and criteria for evaluating the RBR, IRB evaluations, 
although usually based on long-term clinical experience, are unavoidably subjective 
and intuitive. The lack of shared categories and criteria makes it difficult to trace and 
discuss differences of opinion within an IRB, and thereby reduces the chances that 
the evaluation of the ratio between risks and benefits will play a prominent role in 
the final decision regarding the ethical acceptability of the research. The difficulties 
with assessing the RBR sometimes induce IRBs to leave the evaluation primarily to 
the potential research subjects, arguing that it is their right to determine whether, 
from their perspective, the relation of risks to benefits is reasonable. Whether this is 
ethically acceptable, and whether very ill patients are capable of making such 
stressful decisions, remains unclear (Schaeffer et al., 1996; Cox & Avis, 1996; 
Cheng et al., 2000; Montgomery et al., 1999; Huizinga et al., 1999; Davis et al., 
1998).  
The most important contributions to the study of RBR assessment of medical 
research involving humans have been those of Levine and Meslin (Meslin, 1989; 
Meslin, 1990, 1993a,b; Meslin et al., 1994; Levine, 1978; Levine, 1986; Martin et al., 
1995). Levine (1986) developed a set of categories to distinguish between risks and 
benefits for participating patients, for future patients and for society at large 
(scientific progress). These categories have been further refined by distinguishing 
between different kinds or dimensions of risks and benefits for participating patients 
(e.g. physical, psychological, social). Meslin (1989) devoted special attention to risk 
assessment by IRB members. He identified three ‘decision-making processes’ in risk 
assessment: identification, estimation and evaluation of risks. Using Levine’s and 
Meslin’s distinction between different types of risks and benefits, between ‘risk’ and 
‘harm’, certain and uncertain risks, and between the phases of identification, 
estimation and evaluation of risks, we designed a survey to assess IRB members’ 
assessment of the RBR for a specific phase II cancer clinical trial.  
The current study represents the second stage of a four-stage project 
examining the assessment of the RBR of phase II and III cancer clinical trials by 
IRB members in the Netherlands. The first stage of the study consisted of semi-
structured interviews with 53 IRB members regarding the RBR assessment of phase 
II and III cancer clinical studies in general (Van Luijn, 2000; Van Luijn et al., 2002). 
This second stage of the research addresses three primary questions: (1) What risks 
and benefits do IRB members identify in a phase II breast cancer trial, and how do 
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they estimate and evaluate these risks and benefits? (2) What is their assessment of 
the risk/benefit ratio and the ethical acceptability of the protocol, and is there a 
relationship between the various risks and benefits and the assessment of the RBR, 
and the ethical acceptability of the trial? and (3) Are there systematic differences in 
assessment of the risk/benefit ratio and the ethical acceptability of the protocol as a 
function of IRB members’ background characteristics?  
5.2     Subjects and methods 
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Study subjects, protocol evaluation and questionnaire  
The study was conducted in 1998–1999. The IRBs of 8 Dutch academic 
hospitals and specialized cancer centers were asked to participate in the study. We did 
not select non-academic hospitals because they do not evaluate sufficient numbers of 
cancer clinical trials to be appropriate candidates for such a study. Five of the 8 IRBs 
agreed to participate. All members of these IRBs (N=64) were invited to take part in the 
first stage of the study, of whom 52 agreed to do so. One IRB member of the IRB of a 
sixth Dutch teaching hospital also agreed to participate. The primary reason for not 
participating was constraints on time. Of these 53 IRB members, 10 declined to 
continue participation in this second stage of the research, again, due largely to time 
constraints. The final study sample on which the current analysis was based included 43 
members of 6 IRBs in 6 Dutch hospitals.
4
 
The study sample consisted of oncologists 
(21%), other medical specialists (19%), family physicians (5%) nurses (19%) and other 
disciplines (36%), including four pharmacists, two ethicists, two behavioral scientists, 
one statistician, and others. Respondents’ age ranged from 28 to 69 years. The majority 
was male (65%). Nine percent had been IRB members for less than 1 year, 47% for 1-4 
years, 23% for 4-7 years, and 21% for longer than 7 years.  
 
An American phase II breast cancer clinical trial –that had been approved in 
1997– was selected for the study from the website of the National Cancer Institute.5
 
We 
decided against a European or a Dutch protocol to avoid the chance of distortions in the 
results due to the possible familiarity of the research subjects with the protocol. This 
phase II trial was designed to investigate the efficacy and toxicity of allogeneic stem 
cell transplantation in combination with high doses of chemotherapy for patients with 
metastatic breast cancer. We selected a trial involving a very intensive treatment 
because we believed this to be the most effective approach to investigating the process 
of risk/benefit assessment. This trial differs from the usual phase II studies because it 
was expected to have high risks as well as potentially large benefits, while most phase II 
trials are expected to be less risky as well as less beneficial. The rationale for using this 
“atypical” trial was as follows. We expected that such a trial would result in more 
variation in IRB members’ assessments of the risk/benefit ratio and of the ethical 
acceptability of the protocol than a study with high risks but small benefits or vice 
versa, or a study with low risks as well as small benefits. The protocol evaluation was 
conducted by means of a questionnaire consisting primarily of closed-ended questions. 
We used closed questions, because open questions about the protocol evaluation would 
                                                 
4 The hospitals were the Utrecht Academic Hospital, the Vrije Universiteit Medical Center in Amsterdam, 
the Rotterdam Academic Hospital, the Leiden Academic Hospital, the Netherlands Cancer 
Institute/Antoni van Leeuwenhoek Hospital in Amsterdam and the Daniel den Hoed Hospital in 
Rotterdam.  
5 The trial was used with permission of the authors and is entitled A Pilot study of Allogeneic Peripheral 
Blood Stem Cell Transplantation for Patients with Metastatic or Recurrent Breast Cancer Using a 
Conditioning Regimen of Busulfan and Cyclophosphamide.  
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be asked in in-depth interviews in the third phase of the research project. The 
questionnaire had been previously pilot-tested among 5 IRB members or former IRB 
members, none of whom participated in the main study. The respondents were asked to 
study the protocol and the patient information, to complete the questionnaire and to 
return it by mail. The procedures took approximately two hours: one hour for studying 
the protocol and 30 to 45 minutes to fill out the questionnaire.  
The following topics were included in the questionnaire: (1) the identification 
and estimation of the inconvenience, toxicity, psychosocial distress, and the benefits of 
trial participation to patients, (2) the identification and estimation of benefits to future 
patients and medical science, (3) the evaluation of the relative importance of specific 
risks and benefits, (4) the assessment of the overall risk/benefit ratio of the study, and (5) 
the assessment of the ethical acceptability of the study. The questions that were asked 
were based on the literature and can be found in the Appendix (Meslin, 1989; Meslin, 
1990, 1993a,b; Levine, 1978, 1986; Meslin et al., 1994, Martin et al., 1995). Although 
this protocol does not provide any data about psychological and social risks, we have 
asked whether IRB members believed these type of risks were present in the study. The 
questions concerning the identification and estimation of the toxicity were based on a 
predetermined list of toxicities drawn from the protocol itself. The specific aspects of 
possible treatment toxicity that were assessed included: likelihood, severity, duration, 
reversibility and amenability to treatment. The only aspects considered to be relevant 
for assessing the psychosocial burden of the treatment were likelihood, severity, and 
duration. The only aspects considered to be relevant for assessing the benefits of 
treatment were likelihood, duration and importance. The importance of the benefits of 
the treatment was assessed directly, while that of the risks was captured by the severity 
rating.  
It might be argued that the details presented on the rating of the toxicity and 
benefits would be more relevant if a comparison were made with the actual ‘facts’ as 
stated in the protocol. However, in this study such a comparison was not of primary 
interest or the focus of research.  
 
 
 
Statistical Analysis  
Descriptive statistics were generated with the SPSS computing program (SPSS, 
Inc, Chicago, IL). The X
2
 statistic was used to test the relationship between the 
evaluations of the risks and the benefits on the one hand, and IRB members’ final 
judgments on the protocol on the other. We compared the evaluations of the risks and 
benefits of (1) IRB members who believed the risks outweighed the benefits (n=13) 
with those of IRB members who believed the benefits to outweigh the risks, or who 
believed risks and benefits were approximately equally weighted (n=24); and (2) of IRB 
members who would approve the protocol without revision (n=16) with those of IRB 
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members who would approve the protocol after revision or who rejected the protocol 
(n=26). We considered using multiple regression techniques to predict the RBR and 
ethical acceptability of the trial, using the various specific benefits and risks as 
predictors. However, the statisticians we consulted advised against using such an 
approach due to missing data on the individual data level.  
The X
2
 statistic was also used for testing the relationship between professional 
status, length of IRB membership, age and sex, and IRB members’ final judgements on 
the protocol. We compared the assessment of the risk/benefit ratio, and the assessment 
of the ethical acceptability of the protocol of: (1) physicians (n=19) versus other 
professionals (n=24); (2) oncology specialists (n=9) versus the other IRB members 
(n=34); (3) nurses (n=8) versus the other IRB members (n=35); (4) IRB members with a 
membership of four years or less (n=24) versus those who had a longer association with 
an IRB (n=19); (5) IRB members younger than 40 years (n=7) versus those 40 years of 
age or above (n=36); and (6) female (n=15) versus male IRB members (n=28). Multiple 
logistic regression analysis was used to simultaneously examine the association between 
the IRB members’ sociodemographic and professional characteristics and their final 
assessments of the RBR and ethical acceptability of the protocol.  
 
 
5.3     Results 
 
Identification and estimation of risks and benefits  
 
Inconvenience  
As shown in Table 5.1, hospital admission and time investment (travel, waiting 
etc.) were rated as the most inconvenient aspects of trial participation: 93% and 72% of 
the IRB members estimated these aspects as very or fairly inconvenient. Additional 
examinations and extra control visits were rated by 73% and 56% of the respondents as 
very or fairly inconvenient.  
 
 
 
 
Table 5.1: Estimation by IRB members of the inconvenience of the phase II study for 
participating patients (N=43) 
 
                                                                  Very Fairly Not very Not at all   Not applicable a 
     
Hospital admission 35% 58% 7% 0% 0% 
IV treatment   5% 28% 65% 2% 0% 
Additional examinations 17% 56% 27% 0% 0% 
Extra control visits  7% 49% 39% 0% 5% 
Time investment (travel, waiting etc.)          23%           49% 23% 5% 0% 
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a 
Respondents could choose this alternative when they believed a certain form of inconvenience was not 
present in the trial.  
Toxicity  
Table 5.2 presents the evaluation of the most common toxicities along 5 axes: 
likelihood, severity, duration, reversibility and amenability to treatment. There was 
broad agreement among IRB members on the expected toxicity of the treatment: hair 
loss, diarrhea, nausea, vomiting, fatigue and organ toxicity were estimated by most IRB 
members as very to fairly likely. Additional toxicities expected by IRB members to be 
very or fairly likely were: mucositis, infection, fertility problems/damage to offspring, 
bleeding, change of skin color, high blood pressure, tremors, painful hands and feet, 
stomatitis, haematuria, genetic disturbances, and rejection of donor bone marrow.  
Most respondents rated these toxic effects as fairly severe to life threatening, expected 
hair loss and fatigue to last for some months to years, and 30% and 44%, respectively, 
expected organ toxicity and cognitive neurological problems to last for some months to 
years. Although hair loss, diarrhea, and nausea and vomiting were expected to be 
reversible, fatigue and organ toxicity were typically not. Also, half of the respondents 
expected cognitive/neurological problems to be irreversible or sometimes irreversible. 
Although most expected some toxic effects to be amenable to treatment, for hair loss 
and fatigue this was not the case. Furthermore, half of the IRB members expected organ 
toxicity and cognitive/neurological problems, and more than one-third other toxicity, 
not to be treatable. Only a small percentage of respondents did not know how to 
estimate the likelihood, severity, duration, reversibility and amenability to treatment of 
toxic effects.  
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Table 5.2: Estimation by IRB members of the likelihood, severity, duration, reversibility and amenability to treatment of possible toxicity to 
patients during and/or after the experimental treatment (N=43)  
 LIKELIHOOD    SEVERITY    DURATION   REVERSIBILITY  AMENIBILITY TO 
TREATMENT  
 Very 
high 
+ 
fairly 
high  
Low 
+ 
very 
low  
 Don’t 
know 
Mild  Fairly 
severe  
Severe   Life 
threatening  
Don’t 
know 
Acute* 
or 
short 
term  
Chronic**   Don’t 
know 
Reversible  Sometimes 
irreversible 
+ 
irreversible  
Don’t 
know  
Ame- 
nable to 
treatment 
Not 
amenable  
to 
treatment  
Don’t 
know  
Hair loss  84%  7%   9 33 20 37  0 10 17 73  10 79 13 8 9 88 3 
Diarrhea  75%  13%   12 3 63 22  2 10 86 2  12 76 17 7 93 5 2 
Nausea  81%  10%   9 7 45 38  0 10 87 5  8 80 15 5 98 0 2 
Vomiting  86%  3%   11 2 45 42  0 11 89 3  8 84 8 8 90 5 5 
Fatigue  79%  14%   7 6 48 38  0 8 15 75  10 22 68 10 4 88 8 
Organ 
toxicity 
(heart, 
kidney and 
liver) 
63%  28   9 0 22 35  33 10 32 30  38 12 73 15 27 48 25 
Cognitive 
neurological 
problems 
37%  58   5 15 28 38  3 16 31 44  25 22 50 28 11 52 37 
Other  35%  58   7 5 37 21  26 11 56 22  22 52 37 11 44 39 17 
 
* Acute or short term = some days to some weeks  
** Chronic = some months to years  
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Psychosocial distress  
Ninety-three percent of the IRB members believed trial participation would 
entail psychological distress for the patient beyond that caused by the illness itself (data 
not presented in tabular form). As shown in Table 5.3, approximately 50% expected 
patients to experience depression, 79% stress, and 88% uncertainty as a result of trial 
participation. Other forms of psychosocial distress, such as loneliness, donor 
dependence, and fear were identified by 16% of the IRB members. Most respondents 
rated depression, stress, and uncertainty as fairly or very severe. More than one-third 
expected depression, stress and other manifestations of psychological distress to last for 
some months to years, while two-thirds expected uncertainty to last that long or longer. 
Most IRB members were able to estimate the likelihood, severity and duration of the 
psychological burden.  
 
Seventy-two percent of respondents believed trial participation to be a social 
burden for the patient (not presented in tabular form). As reported in Table 5.3, two-
thirds expected a strain on relationships with partners and on other social contacts. 
Seven percent also mentioned long periods of illness or a strain on the patient’s 
professional life as expected stressors. Most IRB members rated the extra strain on the 
relationship with partners and other social contacts to be fairly severe or severe, while 
about half expected this to last for some months to years.  
 
Benefits to participating patients  
As indicated in Table 5.4, 40% of respondents expected tumor remission and 
35% a longer symptom-free period to be fairly or very likely. Only a minority of IRB 
members expected that other benefits would accrue to patients (e.g., 16% longer overall 
survival, 14% less toxicity, 7% less pain, and 7% a better quality of life). Two-thirds of 
the respondents believed that trial participation would provide hope to patients. The 
majority of IRB members expected tumor remission, prolongation of life, a longer 
symptom-free period, other toxicities, and hope to last for some months to years; other 
potential benefits such as less toxicity than an alternative treatment (or no treatment), 
less pain, and a better quality of life, were expected to last only several days or weeks. 
Approximately two-thirds of the respondents evaluated the benefits to patients as very 
or fairly important and about one-third as not that important, unimportant or unknown.  
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Table 5.3: Estimation by IRB members of the likelihood, severity and duration of possible extra psychosocial burden to patients 
during and/or after the experimental treatment (N=43) 
 
 
 
LIKELIHOOD      SEVERITY     DURATION   
 Very 
high + 
fairly 
high 
Low 
+ 
very 
low  
Don’t 
know  
* Not 
applicable  
Did not  
answer 
question 
Not  
severe 
Fairly  
severe 
+ 
severe 
+ very 
severe 
Don’t 
know 
 Not 
applicable 
Did not  
answer 
question  
Acute 
or 
short 
term** 
Chronic 
***  
Don’t 
know 
Not 
applicable 
Did not  
answer 
question 
Psychological burden     
Depression  51% 35% 5%  9% 0% 13% 65%  11%  11% 0% 22% 43% 24% 11% 0% 
Anxiety  79% 12% 0%  9% 0% 8% 80%  2%  10% 0% 35% 40% 15% 10% 0% 
Uncertainty  88% 3% 0%  9% 0% 7% 81%  2%  10% 0% 14% 64% 12% 10% 0% 
Other  16% 70% 5%  9% 0% 0% 50%  17%  33% 0% 8% 42% 17% 33% 0% 
Social burden     
Extra strain on 
relationship 
with partner 
 
61% 9% 2% 28% 0% 3% 62%  5%  30% 0% 8% 45% 17% 30% 0% 
Extra burden 
other social 
contacts 
 
63% 7% 2% 28% 0% 7% 58%  7%  28% 0% 5% 49% 18% 28% 0% 
Loss of 
prestige  
 
5% 60% 7% 28% 0% 29% 10%  22%  39% 0% 7% 13% 40% 40% 0% 
Other  
 
7% 63% 2% 28% 0% 0% 25%  0%  75% 0% 0% 25% 0% 75% 0% 
 
* Not applicable = percentage of IRB members that did not expect extra psychosocial burden to patients or did not know this; they did not answer the 
questions about the likelihood, severity and duration of extra psychosocial burden to patients. **Acute or short term = some days to some weeks.  
*** Chronic = some months to years  
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Table 5.4: Estimation by IRB members of the likelihood, duration and importance of the possible benefits of the experimental 
treatment to the participating patients (N=43) 
 
 
  LIKELIHOOD    DURATION    IMPORTANCE   
 Very 
high + 
fairly 
high  
Low 
+ 
very 
low + 
zero  
Don’t 
know  
Did not 
answer 
question  
Some 
days to 
some 
weeks  
Some 
months 
to years  
Don’t 
know 
Did not 
answer 
question 
Very 
large + 
fairly 
large 
Very 
little 
+fairly 
little  
Don’t 
know 
Did not 
answer 
question 
Tumor remission  40%  41%  9%  0%  7%  63%  30%  0%  62%  30%  8%  0%  
Prolongation of 
life  
16%  75%  9%  0%  11%  62%  27%  0%  69%  26%  5%  0%  
Longer 
symptom-free 
period  
35%  58%  7%  0%  17%  59%  24%  0%  71%  24%  5%  0%  
Less toxicity 
than alternative 
treatment  
14%  72%  21%  0%  24%  16%  60%  0%  62%  19%  19%  0%  
Less pain  7%  72%  21%  0%  16%  28%  56%  0%  65%  19%  16%  0%  
Better quality of 
life  
7%  72%  21%  0%  7%  43%  50%  0%  65%  19%  16%  0%  
Hope 65%  28%  7%  0%  11%  64%  25%  0%  58%  31%  11%  0%  
Other  7%  93%  0%  0%  0%  67%  33%  0%  67%  0%  33%  0%  
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Benefits to future patients and science  
Sixty-eight percent of the IRB members were unable to estimate how many 
patients in the Netherlands would benefit annually from the experimental treatment, 
should it prove effective. Most members rated the clinical trial as fairly to very 
important (8% of very great importance, 39% of great importance, 39% of moderate 
importance).  
 
 
Evaluation of specific risks and benefits, assessment of the risk/ benefit ratio, and 
ethical acceptability of the protocol  
 
Evaluation of risks and benefits 
The possible advantages and disadvantages of the experimental treatment to the 
patients were rated as fairly or very important by 63% and 91% of the IRB members, 
respectively. The importance of the trial to future patients and science was rated as high 
by 23% and 10%, respectively (Figure 5.1). Although nearly all (98%) of the 
respondents rated toxicity as the most important risk of the trial treatment, they also 
evaluated the inconveniences and the psychological burden to patients as very or fairly 
important in their risk/benefit assessment of the trial. 
 
 
0% 20% 40% 60% 80% 100% 
The advantages and disadvantages in general 
The possible advantages of the experimental treatment to the patient 
The possible disadvantages of the experimental treatment to the patient 
The importance of the research to science 
The importance of the research to future 
patients 
The possible advantages of the alternative (e.g. no treatment) to the patient 
The possible disadvantages of the alternative (e.g. no treatment) to the patient 
Specific risks 
The inconveniences of the research to the patient 
The toxicity of the research to the patient 
The extra psychological burden of the research to the patient 
  The extra strain posed by the research on  
patients’ relationships with partner, family and friends 
Very  Fairly Not very Not at all  Don’ t know 
 
Figure 5.1: The weight given by IRB members to different advantages and 
disadvantages  
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of the phase II study (N=43) 
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Final assessment of the risk/benefit ratio (RBR) and the ethical acceptability of the 
research  
Thirty percent of the IRB members believed that the risks of the protocol 
outweighed the benefits, 21% believed that the benefits outweighed the risks, and 35% 
assigned approximately equivalent weights to the risks and benefits (not in tabular 
form). Thirty-seven percent of the IRB members would approve the protocol and 44% 
would recommend approval following revision. Although 44% of the IRB members 
believed that the risks outweighed the benefits or were unable to evaluate the 
risk/benefit ratio, only 18% would reject the protocol or could not judge its ethical 
acceptability. There was a significant relationship between the assessment of the RBR 
and of the ethical acceptability of the trial (p< .031). Most of the IRB members (83%) 
who believed that the risks of the protocol outweighed the benefits, would reject the 
protocol; 17% of them would approve the protocol or would approve following revision. 
More than half (54%) of the IRB members who believed the benefits outweighed the 
risks or who assigned approximately equivalent weights to the risks and benefits, would 
approve it; less than half would reject it or would approve following revision.  
Differences in assessment  
 
Differences in overall assessment of the RBR and the ethical acceptability as a function 
of ratings of specific risks and benefits  
There were a number of significant associations observed between the 
assessment of specific risks, and particularly the duration of such risks, and the overall 
RBR assessment (Table 5.5). The ratings of the inconvenience and benefits of the 
treatment to participating patients had no or only limited effect on the overall RBR 
assessment (Tables 5.5 and 5.6). Importance of tumor remission was related to the RBR 
assessment, and duration of tumor remission and duration of a symptom-free period, 
were significantly related to both the assessment of the RBR and the ethical 
acceptability of the trial. IRB members who believed that the risks outweighed the 
benefits rated the organ toxicity and cognitive/neurological problems to be significantly 
more likely, hair loss, diarrhea, nausea, vomiting and organ toxicities to be of longer 
duration, cognitive and neurological problems to be more often irreversible, and the 
burden of treatment on social contacts to be more severe and of a longer duration.  
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Table 5.5:  Relationship between the various risks and benefits and the assessment of 
the RBR of the phase II study (N=43) a 
 RBR sign. 
 
 
risks outweigh 
benefits  
benefits outweigh the risks or risks and 
benefits weigh nearly the same 
 
Possible toxicity    
likelihood of organ toxicity 
  very high 
  fairly high 
  low 
  very low 
70% 
30% 
0% 
0% 
14% 
46% 
40% 
0% 
.003 
likelihood of cognitive 
neurological problems 
  very high 
  fairly high 
  low 
  very low 
50% 
20% 
20% 
10% 
4% 
23% 
32% 
41% 
.018 
duration of hair loss  
some days 
b
 
some weeks 
some months 
years 
0% 
33% 
44% 
23% 
0% 
13% 
87% 
0% 
.018 
duration of diarrhea  
some days  
some weeks 
some months 
 years 
22% 
67% 
11% 
0% 
68% 
32% 
0% 
0% 
.034 
duration of nausea 
    some days  
some weeks 
some months 
 years 
22% 
44% 
22% 
12% 
61% 
39% 
0% 
0% 
0.22 
duration of vomiting 
    some days  
some weeks 
some months 
 years 
22% 
44% 
12% 
22% 
74% 
26% 
0% 
0% 
0.10 
duration of organ toxicity 
    some days  
some weeks 
some months 
 years 
11% 
11% 
22% 
56% 
24% 
41% 
29% 
6% 
0.35 
reversibility of cognitive 
neurological problems          
    reversible 
    sometimes reversible,    
sometimes not reversible 
    irreversible 
 
 
13% 
 
25% 
62% 
 
46% 
 
54% 
0% 
.009 
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RBR sign. 
 risks outweigh 
benefits 
benefits outweigh the risks or risks and 
benefits weigh nearly the same 
 
severity of extra burden on 
other social contacts 
  not severe 
  fairly severe 
  severe 
  very severe 
0% 
43% 
57% 
0% 
7% 
86% 
7% 
0% 
.037 
duration of extra burden on 
other social contacts         
    some days 
some weeks 
some months 
    years 
0% 
33% 
33% 
34% 
0% 
0% 
92% 
8% 
.025 
Benefits    
duration of tumor remission 
    some days  
some weeks 
some months 
    years  
13% 
25% 
62% 
0% 
0% 
0% 
57% 
43% 
.034 
importance of tumor 
remission 
very important 
fairly important 
not so important 
unimportant 
 
0% 
13% 
37% 
50% 
32% 
47% 
21% 
0% 
.002 
 
 
a
 Only the significant relationships are presented in the Table; for instance there is no significant 
relationship between the inconvenience of the trial and the RBR assessment.  
 
b
 Some days or some weeks= acute; some months to years = chronic 
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Table 5.6:  Relationship between the various risks and benefits and the assessment of 
the ethical acceptability of the phase II study (N=43) a 
 
ethical acceptability 
 approve needs revision 
or reject 
sign.  
Benefits    
duration of tumor 
remission 
    some days  
some weeks 
some months 
    years  
0% 
0% 
44% 
56% 
6% 
12% 
76% 
6% 
.032 
duration of symptom free 
period 
    some days  
some weeks 
some months 
    years  
0% 
28% 
36% 
36% 
7% 
13% 
80% 
0% 
.032 
 
 
a
 Only the significant relationships are presented in the Table.  
 
 
 
Differences in assessment by IRB members’ characteristics  
Physicians did not differ significantly from other professionals in the assessment 
of the risk/benefit ratio and of the ethical acceptability of the protocol. This was also 
true for oncologists compared to other IRB members. Nurses, however, differed 
significantly from other IRB members in their assessment of the ethical acceptability of 
the protocol, as can been seen in Table 5.7.  
Relatively new IRB members (membership of four years or less) were significantly 
more likely to approve the protocol, or recommend approval after revision, than 
members who had a longer association with an IRB. Length of IRB membership did not 
correlate significantly with the RBR assessment of the protocol.  
Older IRB members (>= 40) differed significantly in their RBR assessment from 
younger members: they more often considered the risks to outweigh the benefits (37% 
versus 0%) or the benefits to outweigh the risks (23% versus 0%), and less often found 
risks and benefits to weigh nearly the same (29% versus 71%) or believed that they 
could not answer the question (11% versus 29%) (p = .038). They were also more likely 
to approve the protocol (43% versus 14%) or recommend rejection (20% versus 0%), 
and less likely to recommend approval following revision (34% versus 86%) than 
younger members (p= .047). 
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Table 5.7: Relationship IRB members’ characteristics and assessment of the RBR and ethical acceptability (N=43) a 
 professional status  sign.   length of membership  sign.  age  sign.  gender  sign.  
 nurses  other 
profes-
sionals  
 <= 4 years  > 4 
years  
 < 
403  
>= 
40  
 female  male   
RBR assessment          .038     
risks outweigh benefits        0% 37%     
risks and benefits weigh nearly the same        71% 29%     
benefits outweigh risks        0% 23%     
don’t know        29% 11%     
Assessment of the ethical acceptability    .027   .041   .047    .005  
approve  13% 43%  46% 26%  14% 43%  7% 54%  
revise  87% 34%  50% 37%  86% 34%  73% 28%  
reject  0% 20%  4% 32%  0% 20%  13% 18%  
don’t know  0% 3%  0% 5%  0% 3%  7% 0%  
 
 
a 
 Only the significant relationships are presented in the Table.  
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Significant gender differences were also observed with respect to the assessment of the 
ethical acceptability of the trial protocol. Female IRB members were significantly less 
likely to approve the protocol (75 versus 54%), and were more likely to recommend 
approval following revision (73% versus 28%) than were their male counterparts. There 
were no significant differences in the RBR assessment of male and female IRB 
members.  
When including all IRB members’ characteristics in a multiple logistic 
regression analysis, only gender was associated significantly with the assessment of the 
ethical acceptability of the trial. Female members were significantly more likely to 
reject the protocol or to recommend approval after revision than males (p <. 014). There 
were no significant relationships found in a multiple logistic regression for all IRB 
members’ characteristics and the RBR assessment. 
 
 
5.4     Discussion 
 
The aims of the current study were to examine how individual IRB members 
assess the diverse risks and the benefits of a specific phase II cancer protocol, and to 
examine how they come to their final assessment of the risk/benefit ratio and of the 
ethical acceptability of the proposed trial. First, we were interested in determining what 
type of risks and benefits IRB members identify in evaluating a particular Phase II 
cancer protocol, and how they estimate and evaluate these risks and benefits. The 
results indicate that most IRB members felt competent to estimate specific aspects of 
the risks and benefits such as likelihood and severity –although the expected duration of 
such risks and benefits proved more difficult to evaluate–, to determine the RBR, and to 
assess the ethical acceptability of the trial. These findings are consistent with those 
reported previously for IRB members’ estimations for phase II cancer protocols, in 
general (Van Luijn, 2000; Van Luijn et al. 2002).   
The results also indicate that, besides inconvenience and fairly severe to 
sometimes life threatening physical risks (toxicity), IRB members identified several 
serious psychological and social risks of trial participation. This is in line with the 
distinction made by Levine between different kind of risks in medical experiments for 
participating patients (physical, psychological, social) in medical experiments (Levine, 
1986). Although psychological and social risks were given less weight than 
inconvenience or toxicity, 46% and 70% of the respondents attached very heavy to 
fairly heavy weights to these risks in their risk/benefit assessment of the protocol. The 
results further indicate that, while IRB members believed the research to be important, 
they expected only modest benefits to accrue to the participating patients. Although a 
substantial percentage of IRB members rated benefits to patients such as tumor 
remission (40%) a longer symptom-free period (35%), and hope (65%) to be fairly or 
very likely, only a few expected this to be the case with respect to prolongation of life, 
reduction in pain, less toxicity than an alternative treatment (e.g. no treatment) and a 
better quality of life.  
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Second, we investigated the IRB members’ evaluation of specific risks and 
benefits, the assessment of the risk/benefit ratio and the ethical acceptability of the 
protocol. Although IRB members reported that the possible disadvantages of the 
experimental treatment to participating patients were the most important factors to 
consider in the RBR assessment (more important than benefits to participating patients, 
future patients or medical science), most believed that the benefits outweighed the risks, 
or that risks and benefits had a nearly equal weight, and most wanted the trial to take 
place. Furthermore, as one would expect, a significant association was observed 
between the assessment of the RBR and the assessment of the ethical acceptability of 
the trial; that the IRB members’ evaluation of the RBR plays a significant role in their 
final decision regarding the ethical acceptability of the trial.  
 
Third, we investigated the relationship between the various specific risks and 
benefits, and the assessment of the trial’s RBR and the final judgment on its ethical 
acceptability. Several significant relationships were found between the assessment of 
(aspects of) particular risks and benefits, and the RBR assessment, especially between 
the assessment of the duration of several risks and the RBR assessment. As to the 
benefits, only duration and importance of tumor remission were significantly related to 
the assessment of the trials’ RBR and duration of tumor remission and a symptom-free 
period to its ethical acceptability. Apparently, the IRB members’ RBR assessment is 
mainly based upon weighing the duration of certain risks against the benefits of tumor 
remission and of symptom-free survival. The final judgment on the trial’s ethical 
acceptability is even only significantly correlated to the benefits of the duration of 
remission and symptom free survival. Most cancer patients, however, participate in 
trials because they hope for a treatment effect in terms of prolongation of life 
(Daugherty et al., 1995; Schaeffer et al., 1996; Miller, 2000). Because we did not study 
the letter of informed consent, we cannot say what patients were told about their benefit 
in the trial. However, it can be doubted, considering (1) that patients themselves have to 
carry the risks and (2) the weight they assign to prolongation of life, whether patients 
having the same information as the IRB members, would come to a RBR assessment, 
similar to that of IRB members. At the one hand this observation underlines the need to 
be open and honest in informing the patients, at the other hand it provides a very strong 
argument for taking the perspectives of patients into account when determining the 
RBR of trials.  
 
Fourth, we investigated whether there were systematic differences in assessment 
of the risk/benefit ratio and the ethical acceptability of the protocol as a function of the 
professional background, number of years of committee experience, age and gender of 
IRB members. Physicians and non-physicians did not differ significantly in their 
assessment of the risk/benefit ratio or of the ethical acceptability of the protocol. The 
same was true for oncology specialists compared to other IRB members. Apparently 
there is less difference between medical and non-medical IRB members with respect to 
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the content of their RBR-assessment than with respect to difficulty in making this 
assessment. An earlier study found that non-medical IRB members find RBR-
assessment more difficult than medical IRB members (Berghmans et al, 1996; 1997). 
However, nurses, members with a longer association with an IRB, and female IRB 
members were more critical in their evaluations than other professionals, relatively new 
members, and male IRB members. Older IRB members (> 39) were more extreme in 
their RBR assessment (more often believed that risks outweigh the benefits or vice 
versa) and in their assessment of the ethical acceptability (more likely to approve or 
disapprove the protocol and less likely to recommend approval following revision) than 
younger members. It is possible that members with a longer association with an IRB are 
better able to compare the protocol with other protocols or that they are better informed 
about the risks and benefits of the trial to patients. Nurses and female IRB members 
may be more critical because they can more easily identify themselves with breast 
cancer patients based on their professional experience or simply because they are 
women themselves. In a multivariate analysis including all of the IRB members’ 
sociodemographic and professional characteristics, only gender was found to be 
associated significantly with the assessment of the ethical acceptability of the protocol, 
with female members being significantly more likely to reject the protocol or to 
recommend approval after revision than males (p <. 014). This suggests that it may be 
important to maintain a gender balance in IRB membership, as it appears that women 
may bring a different perspective to the RBR assessment process than their male 
counterparts.  
 
A number of the study’s limitations should be mentioned. First, we only 
evaluated one specific phase II cancer protocol. Although it would have been preferable 
to ask the IRB members to evaluate a range of protocols, this was not feasible given the 
rather labor intensive nature of the research. We believe that the trial protocol that we 
selected for review was reasonably representative of phase II cancer clinical trials in 
general, although, as we stated earlier, the treatment schedule was quite intensive.  
Second, the participants in this study were all drawn from the IRBs of Dutch 
academic hospitals or specialized cancer centers. Whether our results can be generalized 
to other types of hospitals or to other countries is uncertain. The settings in which 
European and American IRBs operate may differ in certain respects. For example, in 
the U.S. there is generally a greater concern with protecting hospitals and physicians 
from possible legal action than is the case in Europe. However, the structure, objectives 
and procedures of IRBs are similar, regardless of whether they are American or 
European. Thus we are fairly confident that our results can reasonably be extended to 
IRBs, in general.  
 
Finally, we would note that our study was based on questionnaire data rather 
than observational data, and that we queried individual IRB members rather than 
investigating the IRBs as a whole. We realize that the decisions taken by IRBs are often 
collective ones, and emerge from discussions and debates that take place during IRB 
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meetings. Nevertheless, each IRB member brings his or her own perspective to such 
deliberations, and is expected to be well prepared to participate actively in the decision 
making process. Thus it is not inappropriate to examine the attitudes and behavior of 
individual IRB members. At the same time, we would recognize the value of other types 
of research (e.g., observational studies) that would better be able to capture the group 
dynamics involved in IRB decision making. In a future paper, we will report the results 
of a latter stage of the current study in which such observational techniques were 
employed.  
 
In summary: First, most IRB members estimated hope (a psychological benefit) 
to patients as as important as physical benefits (about 60% believed physical benefits to 
be fairly or very important, see table 5.4), but more likely (65% believed hope to be 
fairly or very likely versus 7-40% the physical benefits, see table 5.4). Hope is, of 
course, important. Although we did not study why patients want to participate in 
clinical trials, the literature learns that most patients participate hoping that this will 
prolong their lives (Miller, 2000). This hope is in danger of becoming irrational if the 
chances for survival are very low. On the one hand we observe that IRB members 
consider, in contradistinction to tumor remission and a longer symptom-free period, 
survival benefit to be unlikely. On the other hand they regard the psychological benefit 
of hope as important as physical benefits in their RBR assessment. If hope is an almost 
illusionary benefit, is it ethically acceptable to include it in assessing the RBR? We 
know from earlier studies that patients’ and medical doctors’ expectations of benefit of 
participation in medical experiments is different (Daugherty et al., 1995). It would be an 
improvement if patient information sheets pay more attention, as they normally do to 
the risks, to the possible benefits to participating patients. For example they should 
contain more detailed information about the likelihood of prolongation of life. This 
would prevent patients’ hope to become irrational.  
Second, although IRB members found the possible disadvantages of the 
experimental treatment to participating patients the most important factors to consider 
in the RBR assessment (more important than benefits to participating patients, future 
patients or medical science), and although they evaluated the risks to be fairly severe to 
sometimes life-threatening, most believed that the benefits outweighed the risks, or that 
risks and benefits had a nearly equal weight, and most wanted the trial to take place. 
Their final judgment on the trial’s ethical acceptability is only significantly correlated to 
the benefits of the duration of remission and symptom free survival and not to the risks 
or the other studied benefits to participating patients.  
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Appendix: Parameters studied in survey of phase II cancer protocol  
 
Identification and estimation of inconvenience for the research subjects  
“How burdensome do you think this situation is for the patient?” Admission of the patient to the hospital, 
IVs, extra examinations, extra control visits and time investment (travel, waiting etc.). *  
 
Identification and estimation of toxicity for the research subjects  
“What kind of toxicity you believe would happen during and/or after the research?”(one 
could choose between hair loss, diarrhea, nausea, vomiting, fatigue, organ toxicity, 
cognitive neurological problems or still other toxicity) † 
“Indicate the likelihood, severity, duration, reversibility and amenability to treatment for 
the subject during and/or after experimental treatment of the following: hair loss, 
diarrhea, nausea, vomiting, fatigue, organ toxicity, cognitive neurological problems or 
still other toxicity. ‡ 
 
Identification and estimation of psychosocial distress for the research subjects  
“Do you believe participation in the experimental treatment will impose an extra 
psychological burden (beyond the burden imposed by the illness and previous treatment) 
for the patient?” § 
“Do you believe participation in the experimental treatment will place an extra social 
burden (beyond the social burden imposed by the illness and previous treatment alone) 
on the patient?” § 
“Indicate the likelihood, severity and duration of the following psychosocial stress for 
the subject during and/or after the experimental treatment as an extra psychological and 
social burden (over and above the stress related to the illness and treatment): depression, 
stress, uncertainty, extra strain on relationships with partners, extra strain on other social 
contacts and loss of prestige. ¶ 
 
Identification and estimation of benefits to the research subjects  
“What kind of benefits to participating patients you believe would happen during and/or after the 
research?”(one could choose between tumor remission, prolongation of life, longer symptom-free periods, 
less pain, better quality of life, and hope or still other benefits) ** “Indicate the likelihood, duration, and 
importance of the following benefits for the subject during and/or after experimental treatment: tumor 
remission, prolongation of life, longer symptom-free periods, less toxicity than alternative treatment, less 
pain, better quality of life, hope or still other benefits.” ††  
Identification and estimation of benefits to future patients and medical science  
“Indicate how many patients would benefit every year in the Netherlands from the 
experimental treatment should it prove effective.” 
“Indicate the importance of the research study.” ‡‡ 
 
Evaluation of risks and benefits  
“How important in your risk/benefit ratio assessment are the following advantages and disadvantages: the 
possible risks and benefits of the experimental treatment to the patient, the importance of the study for 
future patients and science, the possible risks and benefits of the alternative to the patient, inconveniences, 
toxicity, extra psychological stress and extra strain on the patient’s relationships with his/her partner, 
family and friends. § §  
The RBR assessment of the study  
“What is your final assessment of the risk/benefit ratio of the study?” ¶ ¶  
The assessment of the ethical acceptability of the study  
“What is your final assessment of the study?” ***  
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* Answers were scored on a 4-point Likert scale from ‘very burdensome’ to ‘not 
burdensome at all’. 
 
† If a certain kind of toxicity was believed not to happen, this answer was scored as an 
answer to the next question concerning the likelihood of the toxicity as that the 
likelihood would be ‘not high at all’. If the toxicity was believed to happen, the 
respondent was asked how he estimated the likelihood of this toxicity and his answer was 
also scored as an answer to the next question concerning the likelihood of the toxicity. 
 
‡ Answers were scored on a 4-point Likert scale from: (1) ‘very high’ to ‘not high at all’; 
(2) ‘mild’ to ‘life threatening’; (3) ‘a few days’ to ‘years’; (4) ‘reversible’ to 
‘irreversible’; and (5) ‘amenable to treatment’ to ‘not amenable to treatment’. 
 
§ Answers were scored as: (1) yes, (2) no, (3) don’t know. 
 
¶ The question was scored on a 4-point Likert scale from (1)‘very high’ to ‘not high at 
all’; (2) ‘not so severe’ to ‘very severe’; (3) ‘a few days’ to ‘years’. 
 
** If a certain kind of benefit was believed not to happen, this answer was scored as an 
answer to the next question concerning the likelihood of the benefit as that the likelihood 
would be ‘not high at all’. If the benefit was believed to happen, the respondent was 
asked how he estimated the likelihood of this benefit and his answer was also scored as an 
answer to the next question concerning the likelihood of the benefit. 
 
†† Answers were scored on a 4-point Likert scale from (1) ‘very high’ to ‘not high at 
all’; (2) ‘a few days’ to ‘years’; (3) ‘very important’ to ‘not important at all’. 
 
‡‡ The first question was an open question; answers to the second question were scored 
on a 4-point Likert scale from ‘very important’ to ‘not important at all’. 
 
§ § Answers were scored on a 4-point Likert scale from ‘very important’ to ‘not 
important at all’. 
 
¶ ¶ Possible answers included: (1) ‘the risks outweigh the benefits’; (2) ‘the benefits 
outweigh the risks’; (3) ‘the risks and benefits weigh approximately the same; or (4) 
‘don’t know’. 
 
*** Possible answers included: (1) ‘approve’, (2) ‘needs revision’, (3)‘reject’ and (4) 
‘don’t know’. 
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6     Can IRBs assess the heterogeneous and incommensurable risks and 
benefits of research protocols?* 
 
 
Summary 
Institutional review boards (IRBs) are legally required to determine whether 
the relation between the risks and benefits of a proposed study is reasonable. There 
are reasons to doubt whether the decisions of IRBs about risks and benefits are the 
result of a process of systematic comparison and weighing. It is argued that, even if 
there was sufficient information on which to make such decisions, and even if a 
normative consensus about how to categorize and assess the risks and the benefits of 
a study were available, it would still be very difficult, if not impossible to make an 
objective or neutral assessment of the ratio between risks and benefits due to their 
heterogeneous and incommensurable nature. The necessity and possibility of 
revising or reinterpreting the legal requirements surrounding the work of IRBs, or of 
rethinking the tasks that IRBs are required to carry out, are discussed. 
 
 
6.1     Introduction 
 
 The Dutch law on Medical Experiments Involving Human Subjects of 1998 
states in article 3c that an Institutional Review Board (IRB) can only approve a 
research protocol “if it can reasonably be expected that the interest to be served by 
the research is proportional to the burdens and risks for the research subject”. Article 
3g states that it should be clear from the protocol “to what extent the research 
subject can benefit from the research”. Many other countries have regulations 
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specifying similar conditions for the approval of medical research by an IRB. For 
example, in the U.S. the ‘Common Rule’ states at 45 cfr 46.111a(2) that IRBs must 
determine “that risks are reasonable in relation to anticipated benefits, if any, to 
subjects, and the importance of the knowledge that may reasonably be expected to 
result”. The Common Rule requires at 45 cfr 46.116(3) that participants should be 
provided with “a description of any benefits … which may reasonably be expected 
from the research.” Although the wording in the Dutch law is different from that in 
the Common Rule, both presuppose it to be possible to determine that the burdens 
and risks are proportional to the interest to be served by the research (the Dutch law) 
or reasonable in relation to the anticipated benefits for the human subject, together 
with the importance of expected knowledge resulting from the research (the 
Common Rule).
i
 In recent years, various publications have signalled the problems, 
both in theory and in practice, associated with determining the reasonableness of the 
burdens and risks of participating in medical research in relation to the benefits to 
subjects or to  
 
*     A.W. Musschenga, H.E.M. van Luijn, N.K. Aaronson & R.B. Keus. Submitted to IRB: Ethics 
and Human Research.   
society (Levine, 1978; Meslin, 1989; Martin et al., 1995; King, 2000). The main 
problems are: 1) There are limits to the information available to IRBs and research 
subjects for assessing the reasonableness of risks in relation to benefits; 2) A 
normative consensus about how to categorize and assess especially the benefits of a 
study is lacking;
ii
 3) Because of the heterogeneous and incommensurable nature of 
both the risks and the benefits, an objective assessment of whether the relation 
between risks and benefits is reasonable is very difficult or even impossible to 
make.
iii
 
The first problem, the incompleteness of the available information, makes it 
difficult to determine the ratio between risks and benefits (RBR) of a treatment. 
However, the problem is not specific for RBR-assessments, but is common to many 
medical decisions. In our view, the second difficulty, the lack of a normative 
consensus about how to categorize and assess not only the risks but also the benefits 
of a study, can be solved. Authors such as Meslin, Levine and King have made 
important contributions to developing a conceptual framework for describing and 
assessing risks and benefits.
iv
   
 
Our focus in this article is upon the third problem which, in our view, is the 
most difficult one. The heterogeneous and incommensurable nature of both the risks 
and the benefits of a study makes an objective assessment of its RBR very difficult 
or even impossible. By objective assessment we mean an assessment from what 
Nagel would call an objective, neutral, perspectiveless point of view (Nagel, 1986). 
In assessing the RBR of a study, IRBs need to agree upon the relative weight 
attached to specific risks and benefits. However, one cannot assign weights to risks 
and benefits without adopting a particular perspective, consisting of certain (moral) 
background values. Thus, in order to come to an agreement on the RBR, IRB 
members need to have a certain consensus on these background values and their 
ordering. Other IRBs or patients who do not share this view on values and their 
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ordering, may come to a different judgment about the reasonableness of risks in 
relation to benefits.  
This observation has important consequences for the work of IRBs. IRBs are 
legally required to determine whether the relation between the risks and benefits of a 
study is reasonable. If their judgments are so much influenced by their moral 
background values, what relevance and importance should be attached to them? 
RBR-assessment of IRBs do have consequences. Although patients, in considering 
whether to participate in a study, make their own final decisions, the knowledge that 
the study has been reviewed and approved by an IRB does play a role in their 
deliberations (Madsen et al., 2000). However, if patients do not know the values 
underlying an assessment, they are in danger of being misled. In our view IRBs 
cannot meet the normative expectations implied in current laws and rules of diverse 
countries. The problem of the incommensurability of risks and benefits, together 
with the two other issues noted above, results in IRBs being unable to determine 
objectively whether the relation between risks and benefits is reasonable. What they 
actually do when assessing RBR is ensure, on the one hand, that a proposed study 
does not present unacceptable risks for patients and, on the other, that the study has 
some potential to benefit them and/or future patients. However, this is not what is 
meant by assessing whether the ratio between risks and benefits is reasonable or 
proportional. Thus, the actual practice of IRBs in reviewing a study protocol does 
not meet what the legal rules demand from them.  
There are several possible ways to close the gap between legal demands and 
actual practice. One possibility is to adjust the legal rules to the actual practice by 
reformulating the tasks of IRBs. In the revised form the main task of an IRB would 
be to 1) judge the scientific validity and importance of the research, 2) identify and 
estimate the diverse risks and benefits, 3) determine whether the risks are reasonable 
and whether the research has the potential to benefit the research subjects and/or 
future patients and 4) check the correctness and completeness of the information 
provided to patients. This task can only be satisfactorily executed if the protocol 
contains sufficient information on the scientific value of the research, and other 
benefits and risks. In this formulation IRBs would not be required to make a 
complete and comprehensive judgement about the reasonableness of the relation 
between risks and benefits. That judgment would be left to the potential research 
subjects.  
A second approach to closing the gap between actual practice and legal rules 
would be an authoritative (re)interpretation of the rules. This would involve a 
judicial body or other legal institution changing the legal requirement to determining 
whether the risks are acceptable and whether the research has the potential to benefit 
the research subjects and/or future patients. A third approach would be to ensure that 
the actual practice of IRBs conforms more closely to the current rules. 
  
In this article we reflect upon the findings of a four-stage research project on 
the assessment of the risk/benefit ratio of experimental treatments in oncology by 
IRBs. Experimental treatments in oncology differ from other experimental 
treatments in that the risks associated with the treatments are often quite serious. The 
difficulties in determining the ratio between risks and benefits are therefore more 
prominent in clinical oncology than in other medical fields. In section 6.2 we argue 
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that, because of the heterogeneous and incommensurable nature of both risks and 
benefits, an objective assessment of the relative weight of risks and benefits, and 
thereby of the proportionality of their relation, is very difficult if not impossible. In 
section 6.3 we report on our research project. We conclude from this research that 
the judgments of IRB-members on the proportionality (reasonableness) of the risks 
of a research in relation to the potential benefits have only limited relevance for 
patients considering participation in a trial and may even give them a false 
impression of what they can expect from participating. In section 6.4 we discuss 
further the three potential means of closing the gap between the actual practice of 
IRBs in reviewing research protocols and what the legal rules require them to do.  
  
 
 
 
 
6.2     Is an objective assessment of the reasonableness of the risk/benefit ratio 
possible?  
 
IRBs are not only obliged to check whether the risks and benefits of a study 
are clearly explained in the patient consent forms, in a language understandable to 
an average patient. They also have to determine whether the risks for the research 
subject are reasonable in relation to the potential benefits. Under the current 
regulations in countries such as the Netherlands and the U.S., this should be done 
before a study can be approved; thus, before asking potential research subjects to 
participate. This obligation is not covered by the principle of respect for autonomy, 
but follows from the principle of non-maleficence. IRBs should protect research 
subjects against the risks of harm that are not balanced by potential benefits. This is 
the rationale behind RBR assessments. The principle of respect for autonomy only 
demands that investigators provide complete information about the risks and 
benefits of a study to potential research subjects, to enable them to make an 
autonomous and informed decision about participation in a trial. The principle of 
non-maleficence precedes that of respect for autonomy. This is an important point 
since many people wrongly assume that all the current tasks of IRBs flow from the 
principle of respect for autonomy.  
 
Which arguments do we have for stating that an objective assessment of the 
RBR of a study is difficult if not impossible because of the heterogeneous and 
incommen- surable nature of both its risks and benefits? Incommensurability is a 
complex phenomenon which needs clarification. Suppose that you have a discussion 
with a friend about the attractiveness of two career options, say, that of professor 
and that of manager. Considering the required talents and education, both options 
are open to both of you. The overriding value with respect to which you want to 
compare the options is their satisfactoriness; their contribution to a rewarding and 
satisfactory life.
v
 In determining how satisfactory one option is versus the other, 
requires one to reflect upon a number of issues or criteria, including income, 
autonomy, status, fame, social value, excitement, variation, and so on. These values 
refer to different ways in which a career can be “good.” Let us assume that at least 
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some of these values are incommensurable. Calling values incommensurable means 
that each of these values is neither more nor less valuable than others, but that they 
are also not equal. In other words, there is no objective point of view from which a 
ranking of these values can be made. You and your friend might agree that one 
career is better than the other with respect to some of these criteria, while being 
unable to reach a consensus about the overall quality of the two careers. This is what 
Lukes calls ‘overall incommensurability’ (Lukes, 1991: 34).  
 
All of us, from time to time, in our personal lives, are confronted with a 
choice between incommensurable options. Such a choice need not be 
arbitrary. Several authors argue that a justifiable choice between 
incommensurable options can be made by answering the question: What kind 
of a person am I or do I want to be and what kind of a life do I want to have? 
(Kekes, 1993; Taylor, 1985). Taylor characterises what a person must do in 
such a situation as to ‘make the incommensurable commensurable’. A 
comparison always presupposes a specific point of view. In classical 
utilitarianism one makes a choice between alternatives by measuring their 
relative value on a certain scale, using a common denominator such as well-
being or happiness. The choice is then made from an impersonal point of view. 
What Taylor means is that in a situation of choice between incommensurable 
options, commensuration has to take place, not from an allegedly ‘objective’ 
point of view, but from the particular, subjective point of view of the agent 
himself. Lukes calls this ‘specific commensurability’ (Lukes, 1991: 48-49). 
When reflecting upon several career options, it is often not clear to an 
individual which direction he wants his life to take. It does not help him to 
focus upon the intrinsic merits of the respective options. He has to determine 
for himself whether, for example, to become a professor or a manager fits into 
the kind of life he wants to live. A career not only consumes a great deal of 
your time and energy, it also influences the kind of person you become and 
need to become. The virtues of a good professor are not the same as those of a 
good manager. To choose a career is to discover what is important for you, 
which of your talents you want to develop. If you and your friend do not share 
the same subjective point of view, you will not agree about the overall quality 
of the two career options. 
 
The above example can help us in clarifying what IRBs have to do in 
assessing the reasonableness of the relation between the risks and the benefits of a 
study. When we say that the risks and benefits of a study are incommensurable we 
mean, first, that the values associated with risks on the one side and benefits on the 
other are incommensurable, and, second, that the diverse benefits are 
incommensurable. The category of risks comprises diverse issues such as 
inconveniences, and physical, psychological, social and economic harms; that of 
benefits comprises benefits to patients participating in the research (less pain, tumor 
remission, survival, higher quality of life), scientific benefits (increase of knowledge 
about the effects of diverse treatments), and social benefits (benefits to future 
patients, to their families, to society). Both risks and benefits affect diverse domains 
of health status. Additionally, benefits accrue to diverse stakeholders: the research 
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subjects, future patients, and medical science. Thus, we are confronted with two 
types of incommensurability: intrapersonal and interpersonal.  
 
A further complication in assessing the reasonableness of risks in relation to 
benefits is that there is usually more known about the (nature, extent, and probability 
of) risks than about the (nature, extent and probability of) benefits. A last point is 
that, in making an RBR-assessment, IRBs cannot confine themselves to the 
experimental treatment; they also have to take the context into account. What 
alternatives are available for patients? In phase-II studies, designed to provide initial 
information about the effectiveness of a treatment, there are often no alternatives. 
For patients who are asked to participate in phase-III studies, designed to determine 
whether a new treatment is superior to a standard one, the standard treatment is 
always available, even outside the context of the study. Thus, the assessment of the 
RBR of a study will take place against the background of the available alternatives 
and their risks and benefits. 
Let us assume that the IRB consists of highly competent and experienced 
members. Let us also assume that they share a conceptual framework for describing 
risks and benefits, and have sufficient information for identifying the risks and 
benefits of the study. To assess the reasonableness of the relation between the risks 
and the benefits of an experimental treatment, an IRB has to weigh the risks against 
the benefits. As was the case in our example of career options, the incommensurable 
can only be made commensurable by taking a particular point of view. This point of 
view consists of certain values, goals, beliefs about the value of (the prolongation of) 
life and its quality, and other (‘altruistic’) values. Although IRB members may differ 
as to these values, goals and beliefs, the obligation to make statements about the 
RBR of the studies they are reviewing induces IRBs to develop a – usually implicit – 
common view which is acceptable to all members. This explains why IRBs usually, 
at least in the more familiar, less complex cases, succeed to agree on the RBR of a 
study. The consensus or compromise on these values, goals and beliefs may be 
purely local. Other IRBs may have different views. This may partly explain the 
diversity in RBR assessment between IRBs which has been observed by several 
authors (Foster, 1995; Churchill et al., 2003).
vi
 More important is the possible 
difference in point of view between the IRB and the potential research subjects. 
Thus, when an IRB assesses the relation between the risks and the benefits of a 
study as reasonable, one always has to ask: reasonable from which/whose point of 
view? Other studies confirm our view that extra-scientific, factors such as value 
judgments or attitudes towards risks, play an important role in assessing the weight 
attached to risks and benefits.
vii
 
 
 
6.3     The risk benefit assessment of cancer clinical trials by IRB members 
 
The problem of the heterogeneity and incommensurability of risks and 
benefits may be most prominent in oncology clinical trials. This was one of the main 
reasons for examining in more detail how IRB members assess the risk/benefit ratio 
and ethical acceptability of experimental treatments in oncology. We designed a 
study that was divided into four interrelated stages: 1) semi-structured interviews 
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with 53 IRB members to determine their attitudes, beliefs and experiences in 
evaluating the RBR of phase II clinical trials, in general, 2) evaluation of a phase II 
and a phase III clinical trial protocol by 43 and 41 of those members respectively, 3) 
in-depth interviews with IRB members about those specific protocol evaluations, 
and 4) observation and analysis of IRB meetings. The results from the first through 
fourth stages of this investigation have been published (Van Luijn, 2000; Van Luijn 
et al., 2002) or will be reported in subsequent articles. 
 
We will only summarize here those findings that are relevant to the 
subject matter of this article. In the first stage of our research we investigated 
four aspects of the risk-benefit assessment process: 1) identification of the 
risks and benefits of phase-II clinical oncology trials, 2) estimation of the 
amount of information needed to make a risk-benefit assessment and 
whether such information is available in phase-II clinical oncology trials, 3) 
self-reported competence of IRB members to make a risk-benefit 
assessment and 4) evaluation of specific risks and benefits for patients 
participating in phase-II clinical oncology trials, for future patients, and for 
medical science. The results of this first stage of our research  indicated that 
the absence of criteria and uncertainty about the benefits to patients and the 
rationale of the study make RBR assessments of cancer clinical trials difficult 
for many IRB members. Moreover, most IRB members expressed a desire to 
receive additional information and education in assessing the RBR of such 
trials. This finding suggests that the IRB members lack criteria for decision 
making about the risk benefit ratio of those protocols.viii Another relevant 
finding from this stage of the research was that between one-quarter and 
one-third of the respondents indicate that the clinical trial protocols provide 
insufficient information regarding the likelihood, magnitude and duration of 
both the risks and benefits. Few members reported weighing risks and 
benefits in a systematic manner, but rather relied on global impressions or 
preferred to leave such matters to the IRB as a whole or to their patients 
(Van Luijn et al., 2002).  
 
The main conclusions of the second stage of the study, in which a 
specific phase II breast cancer protocol was evaluated by 43 IRB members 
were:ix 1) Most IRB members felt competent to estimate specific aspects of 
the risks and benefits, such as likelihood and severity, to determine the RBR, 
and to assess the ethical accetability of the trial. 2) Although IRB members 
stated that they attach a heavy weight to the risks, their final judgment on the 
trial’s RBR and ethical acceptability was significantly correlated only with the 
benefits (specifically, the duration of tumor remission and symptom free 
survival) to participating patients. Most cancer patients, however, participate 
in trials because they hope for a treatment effect in terms of prolongation of 
life (Daugherty et al., 1995; Schaeffer et al., 1996; Miller, 2000). Thus, 
considering 1) that it is the patients themselves who have to carry the risks 
and 2) the weight they assign to prolongation of life, it is questionable 
whether patients having the same information as the IRB members would 
come to an RBR assessment similar to that of IRB members.  
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6.4     How to close the gap between practice and legal rules  
 
One can question whether patients, from their perspective, will come to 
the same RBR assessment as IRBs. If this doubt is grounded, one should ask 
what relevance can be attached to an IRB’s statement that the ratio between 
the risks and the benefits of a study is reasonable. Imagine someone who 
wants to invest his money and goes to his bank for advice. The bank mentions 
some funds in which he can safely invest his capital. 'Safely' only means that 
such an investment will not be too risky. It does not say much, if anything, 
about the percentage of profit he can expect. If the bank was in the position to 
say that he could expect reasonable profit, he might conclude that the profit 
would be at least around the average of comparable investment funds. In our 
opinion, an IRB’s approval of a protocol does not say much more than that 
participation is relatively safe. Patients cannot conclude that the balance 
between the risks and the benefits of a study is reasonable for them, simply 
because the IRB has, as a part of the approval procedure, assessed the RBR 
ratio. They may conclude that the risks are acceptable and that participation 
will provide some benefits. However, this is much less than what the legal 
requirements demand that approval of a study by an IRB denotes. As we have 
seen, the Dutch law states that an IRB can only approve a research protocol 
“if it can reasonably be expected that the interest to be served by the research 
is proportional to the burdens and risks for the research subject”. The U.S. 
Common Rule requires “that risks are reasonable in relation to anticipated 
benefits, if any, to subjects, and the importance of the knowledge that may 
reasonably be expected to result.” Clearly there is a gap between the legal 
rules and what is actually done by IRBs. We see three possible ways to close 
this gap. The first is to change the rules and/or to reformulate the tasks of 
IRBs. In the new formulation IRBs would be required to 1) judge the scientific 
validity and importance of the research, 2) identify and estimate the diverse 
risks and benefits, 3) determine whether the risks are acceptable and whether 
there is potential benefit for the research subjects or future patients and 4) 
check whether the patient forms are accurate and complete. The main 
difference between the current regulations and this alternative is that IRBs 
would no longer be required to determine whether the risks are proportional to 
the benefits. Only patients themselves would then decide whether, from their 
particular perspective, the relation between the risks and benefits (both to 
themselves and to science/society) is reasonable.  
 
This proposal reflects the practice of at least some IRBs.
x
 It does not 
imply a radical change in the work of an IRB; only a recognition of its limits. 
Nonetheless, we should carefully consider possible objections. The first 
objection is whether we can expect patients to make a well-informed decision 
on the reasonableness of the risk/benefit ratio, when even IRB members 
sometimes indicate that they lack information and do not feel competent to 
evaluate the diverse risk-benefit issues. As to the lack of information, we 
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believe that IRBs should be more strict in withholding approval of protocols 
that do not contain sufficient information about risks and benefits. Patients 
should not be asked to participate in a trial if an IRB thinks that there is not 
sufficient information available for them to determine whether there is a 
balance between risks and benefits. The other issue is whether patients are 
competent to assess the RBR-ratio, given the fact that even IRB members often 
doubt their competence in this regard. We do not think that IRB members 
doubt their competence because they lack experience. IRB members usually 
are quite experienced. What they mean when expressing doubts about their 
competence is that they find it difficult to make general, objective statements 
about the weight of the diverse and incommensurable risks of a study in 
relation to its also diverse and incommensurable (potential) benefits. They 
realise that not only does their perspective differ from that of patients, but also 
that the perspective of the patient does not exist. Patients’ perspectives are 
usually quite diverse. Using Taylor’s terminology, there is not a shared 
perspective from which an IRB can make the incommensurable for all 
research subjects commensurable. Patients do not have that problem. They 
only decide for themselves. They are free to weigh risks and benefits from their 
own, personal perspective. We want to stress that, even when the legal 
requirements are brought in line with the current practice, it still remains the 
task of the IRB to identify and estimate risks and benefits, and to see to it that 
information provided to patients does not create false impressions about the 
possible benefits.  
 
A second possible objection to changing the legal requirements is that 
patients, who are seriously ill and who often have to decide quickly about trial 
participation, may not be competent to assess the ratio between risks and 
benefits, especially when it concerns complex trials. We cannot address all the 
issues involved in determining what exactly is meant by ‘competence to 
consent’ and decision making capacity, which criteria one needs to use to 
assess it, and when to apply these criteria. There is no consensus about these 
issues in the literature (VanderVeer, 1986; Berghmans, 2000). We limit 
ourselves to three factors that may influence patients’ capacity to decide 
negatively: the stress caused by the context in which a decision has to be made 
(lack of alternatives, urgency), the complexity of the decision, and the 
tendency to overestimate benefits because of hope. These factors already 
constitute a threat to patients' competence to informed consent under the 
current regulations. What is relevant to discuss here is whether this threat to 
patients’ competence becomes more serious when patients can no longer 
assume that the IRB already has assessed the ratio between risks and benefits 
as being reasonable. On the one hand, we recognise that patients may 
experience the decision as more complex when they think that they cannot rely 
on the IRBs judgment on the risk/benefit ratio. On the other hand, the 
recognition that judgments by IRBs largely reflect the IRBs’ shared values 
and beliefs, might free patients’ decisions from illusions. We realise that many 
patients do not have a clear understanding of their role as research subjects 
because they lack an understanding of what it means to participate in a study, 
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confuse research with treatment or see research as ‘cutting edge’ treatment 
(Daugherty, 1999; Miller, 2000; Joffe et al., 2001; Cox, 2002). This tendency 
to blur the boundary between research and treatment may be particularly 
likely in early clinical trials and when subjects are severely ill (Schaeffer et al., 
1996). As is evident from various studies addressing the question of the 
‘therapeutic misconception’ by research subjects (Appelbaum et al., 1982; 
Appelbaum et al., 1987), many patients in early trials are motivated to 
participate because they expect therapeutic benefit. However, the ‘therapeutic 
misconception’ is probably not only present among patients, but also among 
investigators (Schaeffer et al, 1996; Appelbaum et al., 1982; Appelbaum et al., 
1987; Miller, 2000).  
 
A second way to close the gap between actual practice and legal 
requirements would be an authoritative (re)interpretation of the rules. In that 
case a court or another legal institution would state that the legal requirement 
as to determining the reasonableness of the relation between risks and benefits 
should be conceived as determining whether the risks are reasonable and 
whether the research has the potential to benefit the research subjects and/or 
future patients. This second alternative is different from the first only in 
strategic terms. The choice between these two options will depend on the 
nature of a country's legal culture and legal preferences.  
 
There is also a third way forward that we will discuss only briefly. This 
is to bring the practice of IRBs more in accordance with the literal meaning of 
the legal rules. A possible step in that direction could be that IRBs enlarge 
their perspective by taking account of patients’ views on the relation between 
risks and benefits. This could be done in two ways. First, one could require 
that IRBs also have patients as members.
xi
 Stage 1 of our study, involving 
semi-structured interviews with IRB members about their evaluations of phase 
II and phase III clinical trial protocols, yielded results that are relevant to this 
issue, and that suggest an intriguing paradox.
xii
 The results indicated that most 
IRB members would like to receive additional information and education in 
assessing the RBR of clinical trials, and that most IRB members also believe 
that additional insight into the experiences and perceptions of patients would 
help improve the assessment process. However, only about half of the 
participating IRB members favored having patients as members of IRBs. 
Thus, a proposal to include patients in an IRB most likely will not be widely 
accepted. It may be that IRBs find it sufficient to be informed about the 
experiences and perceptions of patients through nurses and the primary care 
physicians who are traditionally viewed as representing the interests of the 
patients on IRBs. It is also conceivable that the discussions within the IRB can 
supply at least part of the information that is needed. However, our study did 
not investigate this possibility. A second way for IRBs to enlarge their 
perspective is to take account of patients’ trial experiences. As yet, limited 
research has been done into these experiences (see e.g. Madsen et al., 2002).  
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Much can be done to improve the work of IRBs. Above all it is 
necessary to further develop a common conceptual framework for describing 
and assessing both risks and benefits. We believe that IRBs should demand 
that clinical trial protocols contain more precise and reliable information 
about risks and benefits, and that information provided to patients do not 
create false impressions about the potential benefits of the research. However, 
all these measures will not be sufficient to close the gap between the actual 
practice of IRBs in determining whether the relation between risks and 
benefits of a research proposal is reasonable, and the legal requirements. We 
have discussed three possible ways of closing this gap. At this moment we do 
not know which of this is the best and most feasible way forward. Additional 
research and discourse is needed to determine which strategy is optimal.  
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7     Summary and conclusion 
 
 
What are the results of this study and how must they be evaluated? The last 
chapter of the report is divided into three parts. First, we describe in section 7.1 the 
background of the study, the main research question, and the study design. Second, 
in section 7.2 we give a summary of the main empirical and empirical-ethical results 
of the articles in this report. Finally, we draw some conclusions (section 7.3).   
 
 
7.1      Background and research question 
 
Before summarizing the results of the research, we will recapitulate what we 
said in the introduction about the background of the research and the central research 
question. It was clear to us from other studies that not only do IRB members have 
difficulty identifying the relevant risks and benefits of a particular protocol, they 
also find it difficult to compare those risks and benefits because (1) the nature, 
extent and the duration of risks and benefits are often uncertain, (2) the nature of the 
various risks and benefits is very diverse, and (3) all of the risks accrue to the 
research subjects, while some of the benefits accrue to future patients and/or to 
medical science. Moreover, in our opinion the lack of consensus on the content of, 
and categories and criteria for evaluating the RBR render IRB evaluations 
unavoidably subjective and intuitive even though they are usually based on long-
term clinical experience. The lack of shared categories and criteria makes it difficult 
to trace and discuss differences of opinion within an IRB, and thereby reduces the 
chances that the evaluation of the ratio between risks and benefits will play a 
prominent role in the final decision regarding the ethical acceptability of the 
research. This is why we decided to set up this research. We also had some intuitions 
about why assessing the RBR is so difficult which we wanted to examine 
empirically. Firstly, RBR concerns risks and benefits that have impact on different 
dimensions of the health or quality of life of the research subject. We inclined to 
agree with those authors who think that these risks and benefits are 
incommensurable. The problem of incommensurability is aggravated because the 
benefits not only accrue to the research subjects, but also to future patients and for 
medical science. Secondly, the weighing of risks and benefits always takes place 
within a certain context. Decisions about the RBR of a trial depend on whether there 
are alternative treatments and on the quality of these alternatives. 
 
The main research question of this study was: 
 
What risks and benefits do IRB members identify in Phase II and III cancer 
clinical trials, how do they estimate and evaluate these risks and benefits, 
and what is the relationship of the evaluative dimensions of risks and 
benefits (e.g. divers physical, psychosocial risks and benefits to participating 
patients) with the RBR assessment and the ethical acceptability of these 
experiments?What other factors determine these assessments and can IRBs 
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assess the heterogeneous and incommensurable risks and benefits? And 
what does it mean when they cannot?   
Experimental treatments in oncology differ from other experimental 
treatments in that the risks associated with the treatments are usually quite serious. 
The difficulties in determining the ratio between risks and benefits are therefore 
more prominent in clinical oncology than in other medical fields. That is the reason 
why we chose to study the RBR assessment in Phase II and III clinical cancer trials.  
 
In order to answer the main research question of this research, we opted for a 
study design with four stages in which different research methods were used. These 
four stages were: (1) semi-structured interviews with 53 IRB members from six 
research hospitals and specialized cancer centers in the Netherlands, (2) a 
questionnaire about an evaluation of a Phase II breast cancer clinical trial and a 
Phase III lung cancer clinical trial administered to 43 and 41 IRB members from 
those six research hospitals and specialized cancer centers, (3) in-depth interviews 
with 35 of these IRB members about their evaluations in stage 2, and (4) observation 
of meetings of two full IRBs while they were discussing the protocols evaluated in 
stages 2 and 3.  
 
 
7.2     Summary of the empirical and empirical-ethical results 
 
In this section we summarize the main results of the research described more 
extensively in the various articles. 
 
1. What kind of risks and benefits do IRB members identify in Phase II 
cancer clinical trials in general? 
 
All of the respondents identified the toxicity and side-effects of treatment, 
and nearly all the additional burdens associated with trial participation (e.g., frequent 
visits to the hospital, extra tests) as common risks associated with trial participation. 
Less self-evident was that 65% of the respondents identified psychosocial risks 
associated with trial participation. These included uncertainty about what is going to 
happen, a potential (and false) sense of hope about treatment efficacy, confrontation 
with the fact that the disease cannot be cured and that the treatment may be of only 
limited or no direct benefit. Additionally, 20% of the respondents reported a 
decrease in quality of life as a risk of treatment.  
Conversely, 68% of the respondents indicated a number of specific psychological 
benefits associated with participation in a Phase II trial. These included an increase 
in the amount of attention and support received from medical and ancillary health-
care providers, a sense that there is still something that can be done to actively treat 
the disease, as well as a personal feeling of being able to fight back against the 
disease. Approximately one-third of the respondents identified improved quality of 
life, and one-quarter treatment efficacy as a possible benefit. The potential for 
developing more effective cancer therapies was rated as the primary benefit to future 
patients and to the scientific community.    
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2. Is the information available in Phase II cancer protocols adequate 
for evaluating risk/benefit issues? And do IRB members consider themselves 
competent to make risk/benefit assessments? 
 
Only a small minority of the respondents (8%) indicated that Phase II 
protocols typically contain too little information about the types of benefits that 
might accrue to participating patients. However, between approximately one-quarter 
and one-half of the respondents reported that frequently there is insufficient 
information provided about the likelihood, the magnitude and the duration of such 
benefits. IRB members believed that protocols provide sufficient information about 
the types of risks involved in Phase II clinical trials. However, a substantial 
percentage of the respondents indicated that too little information is available 
regarding the likelihood, seriousness, duration and reversibility of those risks (44%, 
36%, 60% and 36% respectively). Almost all of the respondents (90%) indicated 
that sufficient information is provided regarding the potential importance of the 
clinical trial for future patients and for medical science.  
Between 15% and 34% of the IRB members reported that it was (very) 
difficult to judge the various risks and benefits associated with Phase II clinical 
trials, both for participating patients and for future patients and society at large.  
 
3. How do IRB members evaluate specific risks and benefits for patients 
participating in Phase II clinical trials, for future cancer patients, and for 
medical science? Or in other words: How do they weigh risks and benefits 
against each other, and what is the most decisive factor in this decision? 
 
Most IRB members do not weigh risks and benefits against each other in a 
systematic way, but rather try to gain an overall impression (20%), to consider what 
alternative treatments are available (15%), whether one would be willing to undergo 
the trial-based treatment oneself or would advise a family member to do so (10%). 
Seventeen percent of the respondents indicated that they typically leave the decision 
as to whether the benefits of a trial outweigh the risks to the patients themselves, and 
12% reported that it is a task for the IRB as a whole, rather than for himself or 
herself as individual IRB member. 
One-third of the respondents were unable to identify a decisive factor in 
assessing the risk/benefit ratio in Phase II clinical trials because they themselves did 
not systematically assess risk and benefits. The issue reported most frequently as 
being decisive was the potential value of the trial to future patients and to medical 
science (i.e., the potential of finding a more efficacious treatment) (21%). This was 
followed by the risks, burdens and inconvenience to participating patients (18%), the 
expectation that the treatment would be beneficial to the participating patients 
(16%), and feeling comfortable in proposing the trial-based treatment to patients 
(11%).  
 
 4.         Are there systematic differences in the perceived adequacy of 
information typically available in Phase II cancer protocols, and the 
perceived competence to evaluate the scientific and risk/benefit ratio issues 
of those protocols, due to IRB members’ characteristics? 
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When comparing oncology specialists with other IRB members (including family 
physicians), statistically significant differences were observed in: (1) the perceived 
adequacy of information provided in trial protocols about the likelihood of benefits 
(100% versus 68%) and risks (89% versus 49%) to patients, and (2) perceived 
competence in evaluating the toxicity of the treatment (100% vs. 50%), the 
invasiveness of the treatment (100% versus 55%), the originality of the trial (89% 
versus 30%), and the place of the trial in relation to previous research (89% versus 
34%). 
 
5. What are the most difficult aspects of assessing the RBR of Phase II 
and III cancer protocols in general? 
 
Making RBR decisions without clear criteria and in the face of uncertainty 
with regard to patient benefits and study rationale were perceived as the two most 
difficult aspects of the RBR assessment for Phase II and III cancer trials by 62% (for 
Phase II studies) and 39% (for Phase III studies). A minority mentioned other 
aspects as well such as: research confronts patients with difficult choices in the face 
of necessary risks; it is hard to gain a view of all relevant factors; the difficulty of 
withholding treatment because of placebo.  
 
6. Is there a need for more information and education to make RBR 
assessments, and how can RBR assessments be improved? Would 
participation of lay individuals and patients improve the quality of the 
assessments? 
 
Fifty-six percent of the IRB members would like to receive more information 
and training in assessing the RBR of protocols. Approximately half of the 
respondents who expressed an interest in more information or training were 
interested in attending courses or seminars, and one-third reported a need for 
feedback on trial results and on the experience of patients who participate in trials. 
Eight percent was interested in reflection on past decisions and an overview of new 
developments in oncological research. About one-third mentioned still other aspects. 
The percentages do not total 100% because more than one type of support could be 
mentioned.  
Suggestions were made by IRB members to improve RBR assessments, such 
as that more information be placed at their disposal, particularly regarding the 
experiences patients had with participating in trials and their perceptions of the risk 
and benefits.  
 
7.        What is the effect of background characteristics concerning IRB 
members’ ratings on information to and participation of lay individuals and 
patients?  
 
The only significant finding was that fewer oncologists (18%) found that 
more knowledge and education was necessary in making risk/benefit assessments 
than did other professionals (62%). Younger IRB members (age < 40) favored lay 
participation in IRBs more than did older members (70% versus 38%). For the other 
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characteristics no significant relationship was found with respect to lay individuals’ 
membership. The most substantial (although statistically non-significant) difference 
with respect to letting patients participate on IRBs was that fewer physicians (12%) 
found patient IRB participation desirable than did other professionals (35%). 
Relatively new IRB members (those with four or fewer years of experience) were 
significantly more likely to favor patient participation on IRBs than were members 
with more IRB experience (38% versus 4%). Women rejected the idea of patient 
IRB participation significantly more often than men (72% versus 4%).  
 
8. What risks and benefits do IRB members identify in a Phase II breast 
cancer trial, and how do they estimate and evaluate these risks and benefits? 
 
Inconvenience 
Hospital admission and time investment (travel, waiting, etc.) were 
rated as the most inconvenient aspects of trial participation: 93% and 72% of 
the IRB members estimated these aspects as ‘very inconvenient’ orrather 
‘rather inconvenient,’ Additional examinations and extra control visits were 
rated by 73% and 56% of the respondents as ‘very inconvenient’ or‘rather 
inconvenient.’  
 
Toxicity 
There was broad agreement among IRB members on the expected toxicity of 
the treatment: hair loss, diarrhea, nausea, vomiting, fatigue and organ toxicity were 
estimated by most IRB members as ‘very likely’ to ‘rather likely.’ Additional 
toxicities expected by IRB members to be ‘very likely’ or ‘rather likely’ were: 
mucositis, infection, fertility problems/damage to offspring, bleeding, change of skin 
color, high blood pressure, tremors, painful hands and feet, stomatitis, hematuria, 
genetic disturbances, and rejection of donor bone marrow.  
Most respondents rated these toxic effects as ‘rather severe’ to ‘life 
threatening,’ expected hair loss and fatigue to last for some months to years, and 
30% and 44%, respectively, expected organ toxicity and cognitive neurological 
problems to last for some months to years. Although hair loss, diarrhea, and nausea 
and vomiting were expected to be reversible, fatigue and organ toxicity were 
typically not. Also, half of the respondents expected cognitive/neurological 
problems to be ‘irreversible’ or ‘sometimes irreversible.’ Although most expected 
some toxic effects to be amenable to treatment, for hair loss and fatigue this was not 
the case. Furthermore, half of the IRB members expected organ toxicity and 
cognitive/neurological problems, and more than one-third expected other, non-
treatable, toxicity. Only a small percentage of respondents did not know how to 
estimate the likelihood, severity, duration, reversibility and amenability to treatment 
of toxic effects.  
 
Psychosocial distress 
Ninety-three percent of the IRB members believed trial participation would 
entail psychological distress for the patient beyond that caused by the illness itself. 
Approximately 50% expected patients to experience depression, 79% stress, and 
88% uncertainty as a result of trial participation. Other forms of psychosocial 
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distress, such as loneliness, donor dependence, and fear were identified by 16% of 
the IRB members. Most respondents rated depression, stress, and uncertainty as 
‘rather severe’ or ‘very severe.’ More than one-third expected depression, stress and 
other manifestations of psychological distress to last for some months to years, while 
two-thirds expected uncertainty to last that long or longer. Most IRB members were 
able to estimate the likelihood, severity and duration of the psychological burden.  
Seventy-two percent of respondents believed trial participation to be a social burden 
for the patient. Two-thirds expected a strain on relationships with partners and on 
other social contacts. Seven percent also mentioned long periods of illness or a strain 
on the patient’s professional life as expected stressors. Most IRB members rated the 
extra strain on the relationship with partners and other social contacts to be ‘rather 
severe’ or ‘severe,’ while about half expected this to last for some months to years.  
 
Benefits to participating patients 
Forty percent of the respondents expected tumor remission and 35% a longer 
symptom-free period to be ‘rather likely’ or ‘very likely.’ Only a minority of IRB 
members expected that other benefits would accrue to patients (e.g., 16% longer 
overall survival, 14% less toxicity, 7% less pain, and 7% a better quality of life). 
Two-thirds of the respondents believed that trial participation would provide patients 
with hope. The majority of IRB members expected tumor remission, prolongation of 
life, a longer symptom-free period, other toxicities, and hope to last for some months 
to years; other potential benefits such as less toxicity than an alternative treatment 
(or no treatment), less pain, and a better quality of life, were expected to last only 
several days or weeks. Approximately two-thirds of the respondents evaluated the 
benefits to patients as ‘very important’ or ‘rather important.’   
 
Benefits to future patients and science 
Sixty-eight percent of the IRB members were unable to estimate how many 
patients in the Netherlands would benefit annually from the experimental treatment, 
should it prove effective. Most members rated the clinical trial as ‘rather important’ 
to ‘very important.’    
 
Evaluation of risks and benefits.  
The possible risks and benefits of the experimental treatment to the 
patients were rated as ‘rather important’ or ‘very important’ by 63% and 91% 
of the IRB members respectively. The importance of the trial to future patients 
and science was rated as ‘high’ by 23% and 10%, respectively. Although 
nearly all (98%) of the respondents rated toxicity as the most important risk of 
the trial treatment, they also evaluated the inconveniences and the 
psychological burden to patients as ‘very important’ or ‘rather important’ in 
their risk/benefit assessment of the trial.  
 
9.      What is the IRB members’ assessment of the risk/benefit ratio and 
the ethical acceptability of the protocol? Is there a relationship between the 
various risks and benefits and the assessment of the RBR, and the ethical 
acceptability of the protocol? 
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Final assessment of the risk/benefit ratio (RBR) and the ethical acceptability 
of the research 
Thirty percent of the IRB members believed that the risks of the protocol 
outweighed the benefits, 21% believed that the benefits outweighed the risks, and 
35% assigned approximately equivalent weights to the risks and benefits. Thirty-
seven percent of the IRB members would approve the protocol and 44% would 
recommend approval following revision. Although 44% of the IRB members 
believed that the risks outweighed the benefits or were unable to evaluate the 
risk/benefit ratio, only 18% would reject the protocol or could not judge its ethical 
acceptability. There was a significant relationship between the assessment of the 
RBR and of the ethical acceptability of the trial.  
 
Differences in overall assessment of the RBR and the ethical acceptability as a 
function of ratings of specific risks and benefits  
There were several significant relationships between the assessment of 
(aspects of) particular risks and benefits and the RBR assessment, especially 
between the assessment of the duration of several risks and RBR assessment. 
Inconvenience and benefits to participating patients had no or only a few 
significant relationships with this assessment. Duration and importance of 
tumor remission, and duration of a symptom-free period were significantly 
related to both the assessment of the RBR and the ethical acceptability of the 
trial. IRB members who believed the risks to outweigh the benefits, believed 
toxicity and cognitive neurological problems to be significantly more likely, the 
duration of hair loss, diarrhoea, nausea, vomiting and toxicity to be longer, 
cognitive neurological problems to be more often irreversible, and the extra 
burden on other social contacts to be more severe and to last longer.  
 
10.   Are there systematic differences in assessment of the risk/benefit 
ratio and the ethical acceptability of the protocol due to IRB members’ 
characteristics? 
 
Physicians did not differ significantly from other professionals in the 
assessment of the risk/benefit ratio and of the ethical acceptability of the protocol. 
This was also true for oncologists compared to other IRB members. Nurses, 
however, differed significantly from other IRB members in their assessment of the 
ethical acceptability of the protocol.   
Relatively new IRB members (membership of four years or less) were 
significantly more likely to approve the protocol, or recommend approval after 
revision, than members who had a longer association with an IRB. Length of IRB 
membership did not correlate significantly with the RBR assessment of the protocol. 
Some significant relationships were found between age and gender and the 
assessment of the RBR or with the ethical acceptability of the trial.  
When including all IRB members’ characteristics in a multiple logistic 
regression analysis, only gender was associated significantly with the assessment of  
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the ethical acceptability of the trial. Female members were significantly more likely 
to reject the protocol or to recommend approval after revision than males (p <. 014).  
There were no significant relationships found in a multiple logistic regression for all 
IRB members’ characteristics and the RBR assessment.  
 
11. Can IRBs assess the heterogeneous and incommensurable risks and 
benefits of research protocols?  
 
The heterogeneous and incommensurable nature of both the risks and the 
benefits of an experiment make an objective assessment (we mean an assessment 
from an objective, scientific point of view) of its RBR impossible. In assessing the 
RBR of a trial, IRBs need to agree upon the relative weight of specific risks and 
benefits. However, one cannot assign weight to risks and benefits without referring 
to certain extra-scientific, moral background values. Thus, in order to reach 
agreement on the RBR, IRB members need to have a certain consensus on these 
background values and their relative order. Other IRBs or patients who do not share 
this view on values and order may come to a different judgment about the 
reasonableness of risks in relation to benefits.  
In our view IRBs cannot meet the normative expectations implied in current 
laws and rules of diverse countries. The problem of the incommensurability of risks 
and benefits renders them unable to determine objectively whether the relation 
between risks and benefits is reasonable. What they actually do is ensuring that a 
proposed experiment does not present unreasonable/unacceptable risks for research 
subjects and that the study has the potential to benefit them and/or future patients.  
 
12.       Given that IRBs can or cannot assess the heterogeneous and 
incommensurable risks and benefits of research protocols, how does this 
affect the policy and practice of reviewing experimental medical 
treatments?  
 
As said before, in our view the actual practice of IRBs in reviewing a research 
project does not meet the legal requirements. There are several ways to close the gap 
between legal demands and actual practice. First, adjusting the legal rules to the 
actual practice by reformulating the tasks of IRBs. In the revised form the main task 
of an IRB should be 1) to judge the scientific validity and importance of the 
research, 2) to identify and estimate the diverse risks and benefits, 3) to determine 
whether the risks are reasonable and whether the research has the potential to benefit 
the research subjects and/or future patients and 4) to check the correctness and 
completeness of the patient forms. In this formulation IRBs are not required to make 
a complete and comprehensive judgement about the reasonableness of the relation 
between risks and benefits. That judgment is left to the potential research subjects. 
This implies the recognition that only patients themselves should decide whether, 
from their particular perspective, the relation between the risks and the benefits is 
reasonable. It does not imply a radical change in the work of an IRB, only 
recognition of its limits. A second way to close the gap between actual practice and 
legal rules would be an authoritative (re)interpretation of the rules. In that case a 
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court or another legal institution would specify ‘reasonableness’ in order to 
determine whether the risks are in fact reasonable and whether the research in fact 
has the potential to benefit the research subjects and/or future patients. A third way 
is to improve the actual practice of IRBs in such a way that it accords more with the 
rules. A possible step in that direction could be that IRBs enlarge their perspective 
by taking account of patients’ views on the relation between risks and benefits. 
These three ways were presented as possibilities to close the gap between the actual 
practice of IRBs in determining whether the relation between risks and benefits of a 
research proposal is reasonable, and the legal rules for making these assessments.   
 
As said before (see Introduction) not all sub-research questions of the study 
were answered in the articles included in this report. A manuscript about the 
assessment of the risks and benefits of a specific Phase III cancer trial (The 
evaluation of the risk and benefits of Phase II cancer clinical trials by Institutional 
Review Board (IRB) members: A case study) is in preparation. This is also true for a 
manuscript about the considerations of IRB members behind their assessments of the 
RBR and the ethical acceptability, and for a manuscript focused on the deliberations 
in two IRBs about the specific protocols that had been evaluated by the individual 
IRB members in stage II of this study.  
 
 
7.3     Conclusions 
 
In this last section we will present some general conclusions from our study. 
We start with a brief discussion and conclusion with respect to the suitability of the 
conceptual model used in this study for describing and explaining the RBR 
assessment of research protocols by IRB members. We end with a few additional 
conclusions.The aims of the research were:  
 
(6) to provide insight into the impact that judgments on the diverse 
evaluative dimensions of experimental treatments (scientific importance, side 
effects, length of survival, quantity of tumor remissions, symptom-free 
period etc.) have on the final decision about the acceptability of these 
experiments; 
(7) to provide insight into the factors that play a role in balancing the 
heterogeneous and incommensurable burdens and benefits of experimental 
treatments in oncology and that could explain the possible differences in 
evaluations between members of an IRB; 
(8) to contribute to increasing the transparency and the justifiability of 
judgments by IRBs about the proportionality of benefits and burdens of 
experimental treatments in oncology and thereby to enable IRBs to monitor 
the consistency in their judgments and decisions with regard to different 
research protocols;   
(9) to provide insight into what from an ethical point of view should be 
the relation between the principle of respect for autonomy – the liberty of 
research subjects to form, on the basis of their personal preferences and 
values, their own judgment about the proportionality of benefits and burdens 
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of participating in a research project – and the principle of non-maleficence 
that obligates the IRBs to make a general judgment of the ethical 
acceptability of the research; 
(10) to contribute to insight into the feasibility of the legal obligation of 
IRBs in the Netherlands to determine the proportionality of the ratio between 
benefits and burdens of medical experiments with humans.  
 
 
The conceptual model and the RBR assessments by IRB members 
 
The process of the RBR assessment  
In our conceptual model the RBR assessment consists of different processes, 
namely primary and secondary appraisal (i.c. the identification, estimation and 
evaluation of the risks and benefits) and the coping (=decision making) itself (i.c. the 
weighing of risks and benefits, and the emotion-regulating processes). Also a diverse 
range of risks and benefits are distinguished such as physical, psychological and 
social risks and benefits of humane research. The results of this study show that the 
conceptual framework (the distinction between the various processes and the 
different categories and dimensions of risks and benefits) is partly adequate (cf 
articles 1 and 3). IRB members do identify various physical, psychological and 
social risks, and physical and psychological benefits of participation in Phase II 
cancer trials for participating patients, and benefits for future patients and medical 
science. They were able to identify and estimate risks and benefits for participating 
patients according to pregiven evaluative dimensions (e.g. the likelihood, duration 
etc.), and to evaluate benefits for medical science; the benefits to future patients 
were more difficult to evaluate (cf article 3). However, although IRB members can 
answer closed questions in order to identify, estimate and evaluate risks and 
benefits, it is questionable whether this is actually done in this way. First, the 
pregiven risk/ benefit issues inevitably influenced the way they evaluated the 
protocols. Second, only a minority of IRB members assessed the RBR in a 
systematic way, as the semi-structured interview learned. Therefore the conclusion 
must be that identification, estimation and evaluation (according to the model - the 
judgment and evaluation processes), are adequately conceptualized only when there 
is an ideal study situation in which IRB members are forced to think about risks and 
benefits according to extensive survey questions. In normal life, where such a 
laboratory situation is lacking, these processes do not take place so systematically, 
as the semi-structured interview shows. As a rule the RBR assessment is a global 
decision-making process. The distinction in the model between the different 
processes is probably adequate only when ‘ideal’ evaluations take place according to 
pregiven lists of evaluating dimensions.  
 
 Our model also distinguishes between different decision strategies. Some 
of these processes, such as information search processes and interactions with 
others, will probably take place during the collective decision making in IRB 
meetings. However, individual IRB members’ examples of these decision-
making strategies were also found in the empirical data. For example, most 
IRB members do not weigh risks and benefits in a systematic manner, as was 
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already said; rather, they relied on global impressions or preferred to leave 
such matters to the IRB as a whole or to the patients. Weighing of risks and 
benefits is only one decision-making strategy (this can be categorized as 
rational weighing of advantages and disadvantages). Other strategies are 
emotion-regulation processes such as leaving the decision to the patients or 
the IRB as a whole. Also, IRB members sometimes try to imagine that they 
themselves or their loved ones were subjects in the trial they are evaluating 
(mental imaging). Some say this was the only way they were able to come to a 
decision on the RBR. Furthermore, a possible explanation of the fact that a 
number of IRB members could not make an RBR assessment (because they 
lacked criteria) might be that the usual way of making decisions – by mental 
imaging and anticipating behavior – is sometimes inappropriate. This is 
probably due to the fact that IRB members need to decide for others (e.g. the 
participating patients in the trial) and not for themselves.  
            We can conclude that the different decision-making strategies that were 
conceptualized in the model are reflected in the empirical data. 
  
Determining factors  
The model mentions several factors that may determine IRB members’ 
assessment of the RBR of Phase II and III trials. These factors might determine the 
judging and evaluation processes as well as the actual decision making. Only part of 
these factors was actually included in this study. They may be categorized into 
internal (or intermediate) and external factors. Internal factors are factors that 
determine the evaluation and decision-making process, but are part of this process 
itself, such as the evaluation of the different evaluative dimensions of the risks and 
benefits. External factors are factors that determine the evaluation and decision-
making process from the outside (independent factors).  
 
Internal factors  
There were several significant relationships between the assessment of 
(aspects of) particular risks and the benefits, and the RBR assessment of the Phase II 
cancer trial. This was especially so for the assessment of the duration of several risks 
and the RBR assessment (cf article 3). IRB members who believed the risks to 
outweigh the benefits, further believed toxicity and cognitive neurological problems 
to be significantly more likely, the duration of hair loss, diarrhea, nausea, vomiting 
and toxicity to be longer, cognitive neurological problems to be more often 
irreversible, and the extra burden on other social contacts to be more severe and 
longer lasting. Of the benefits only duration and importance of tumor remission, and 
duration of a symptom-free period were significantly related to the assessment of the 
RBR. 
Duration and importance of tumor remission, and duration of a symptom-free 
period were also significantly related to the assessment of the ethical acceptability of 
the trial; other benefits to participating patients or (aspects of) the inconvenience and 
risks were not.  
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External factors  
In the evaluation of Phase II studies in general (article 1), we found 
indications regarding the influence of the perceived adequacy of the information 
typically available in Phase II protocol, and the perceived competence of IRB 
members to make risk/benefit assessments. A substantial percentage of IRB 
members (between 25%-60%) reported that too little information was available 
about more specific issues such as the likelihood, magnitude and duration of such 
risks and benefits. The lack of detail provided in protocols may explain, at least in 
part, the finding that one-third of IRB members do not make a risk/benefit 
calculation at all, and that 17% leave such matters up to patients. Also, a substantial 
minority of IRB members (ranging from 15% to 40%) reported feeling less than 
fully competent to evaluate the risks and benefits associated with Phase II trials and 
the scientific details of these trials. We did not inquire whether in this case the 
relationship of the perceived competence to make risk/benefit assessments and the 
RBR assessment is significant; this will be studied in a future paper. Also the lack of 
decision-making criteria plays a role. A substantial number of IRB members 
reported that they lack criteria to make risk/benefit assessments (cf article 2).  
Finally, several sociodemographic and professional status characteristics 
were, as we have seen, found to be significantly related to the RBR assessment and 
the assessment of ethical acceptability. The IRB members’ age had a significant 
relationship with the outcome of the RBR assessment of the specific Phase II 
cancer trial. In a multivariate analysis, however, the age effect disappeared. 
Professional status (nurse vs. non-nurse), length of membership, age and gender 
had significant relationships with the outcome of the assessment of the ethical 
acceptability of the specific Phase II cancer trial. In a multivariate analysis 
including all of the IRB member’s sociodemographic and professional 
characteristics, only gender was found to be associated significantly, with female 
members being significantly more likely to reject the protocol or recommend 
approval after revision than males.   
 
The conclusion is that several of the factors in the model are associated 
significantly with the RBR assessment, or there were indications for such 
association. Not all relevant factors mentioned in the model were studied so far; 
others will be the subject of future study.  
 
 
Impact of the evaluative dimensions of experimental treatments on the 
assessment of their ethical acceptability  
 
The first aim of the study was to provide insight into the impact that 
judgments on the diverse evaluative dimensions of experimental treatments 
(scientific importance, side effects, length of survival, quantity of tumor remissions, 
symptom-free period etc.) have on the final decision about the acceptability of these 
experiments.  
We have seen that several evaluative dimensions of risk and benefits are 
significantly associated with the RBR assessment. The duration of certain forms of 
toxicity and the duration and importance of a few benefits (tumor remission and 
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symptom-free period) to participating patients have impact on the RBR assessment 
of the Phase II breast cancer trial. IRB members who believed the risks to outweigh 
the benefits, believed toxicity and cognitive neurological problems to be 
significantly more likely, the duration of hair loss, diarrhea, nausea, vomiting and  
toxicity to be longer, cognitive neurological problems to be more often irreversible, 
and the extra burden on other social contacts to be more severe and of longer 
duration. Of the benefits only duration and importance of tumor remission, and 
duration of a symptom-free period were significantly related to the assessment of the 
RBR. 
However only the duration and importance of tumor remission and 
symptom-free period (benefits to participating patients) have impact on the 
assessment of the ethical acceptability of the trial. We cannot say which of 
these evaluative dimensions of the risks and benefits to participating patients 
were most central to the RBR assessment, because our data did not allow us to 
perform the necessary analysis (a multivariate analysis). According to IRB 
members (and as we expected) the benefits to future patients and medical 
science are less important in the RBR assessment of ethical acceptability. We 
did not study however whether there was a significant relationship between the 
evaluation of the benefits to future patients and medical science and the 
assessment of the ethical acceptability of the trial.  
So, only some evaluative dimensions of tumor remission and a symptom-free 
period were significantly related to the assessment of the ethical acceptability of the 
breast cancer trial; other benefits to participating patients or (aspects of) the 
inconvenience and risks were not. This means that tumor remission and a symptom-
free period are the benefits to participating patients that are most important for IRB 
members’ assessments of the ethical acceptability of the trial. These are more 
important than the risks to participating patients, and also more important (as we 
expected) than the benefits to future patients and medical science. This is somewhat 
disconcerting recognizing that most patients participate in trials because they hope 
for a treatment effect in terms of prolongation of life (Miller, 2000).   
 
 
Factors that determine the RBR assessment  
 
The second aim of the study was to provide insight into the factors that play 
a role in balancing the heterogeneous and incommensurable burdens and benefits of 
experimental treatments in oncology and that could explain the possible differences 
in evaluations between members of an IRB. We have seen that several factors play a 
role in balancing the risks and benefits of these treatments. As said before, in our 
empirical studies we found that (or found indications that) these factors are: 
identifications, estimations and evaluations of risks and benefits, the perceived 
adequacy of the information typically available in Phase II protocols, the perceived 
competence of IRB members to make risk/benefit assessments, lack of decision-
making criteria to make these assessments, and several sociodemographic and 
professional status characteristics. As noted, not all relevant factors that play a role 
according to the literature were studied in the articles in this report.  
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Transparency and justifiability of judgments by IRB members and IRBs 
 
The third aim of this study was to contribute to increasing the transparency, 
and the justifiability of judgments by IRBs about the proportionality of benefits and 
burdens of experimental treatments in oncology, and thereby to enable IRBs to 
monitor the consistency in their judgments and decisions in regard to different 
research protocols. With regard to this aim we developed our conceptual model. 
While the model can serve as an aid in making assessments, its concepts and can 
also be used for articulating and justifying the actual assessments, both of IRBs and 
individual IRB members. If IRBs were to use the framework for a detailed 
description of their assessments and decisions in the minutes of their meetings, they 
would avail themselves of an instrument to monitor the consistency in their 
judgments and decisions in regard to different research protocols. Forthcoming 
papers will further contribute to increasing the transparency and justifiability of 
RBR assessments of Phase II and III cancer studies by IRB members and IRBs.  
 
 
Relation between the principles of respect for autonomy and of 
non-maleficence and the feasibility of the legal requirement for 
IRBs to assess RBR 
 
We take the last two aims together. The fourth aim of the research was to 
provide insight into what, from an ethical point of view, should be the relation 
between the principle of respect for autonomy – the liberty of research subjects to 
form, on the basis of their personal preferences and values, their own judgment 
about the proportionality of benefits and burdens of participating in a research – and 
the principle of non-maleficence that obliges IRBs to protect research subjects 
against unnecessary and unreasonable burdens and risks. The fifth and last aim was 
to contribute to insight into the feasibility of the legal obligation of IRBs in the 
Netherlands to determine the proportionality of the ratio between benefits and 
burdens of medical experiments with humans. In many countries RBR assessments 
are regarded as an essential instrument for the protection of research subjects. The 
empirical results suggest that it is difficult or sometimes even impossible for IRB 
member to make an RBR assessment. The philosophical analysis of the incom-
mensurability of risks and benefits explains what one means when saying that it is 
not possible to make an RBR assessment: it is impossible to assess the RBR in an 
objective, scientific way; non-scientific value judgments will always be involved. 
This is probably also the reason why some IRBs are inclined to refer to the principle 
of respect for autonomy and leave the assessment of RBR to the potential research 
subjects. What has to be reconsidered is not the relationship between the principle of 
respect for autonomy and the principle of non-maleficience. In our view the 
principle of non-maleficence still outranks that of respect for autonomy. What has to 
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be reconsidered is the scope of that principle: whether or not the requirement that 
IRBs make an RBR assessment should be maintained. 
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Notes 
 
i
 The various legal texts dealing with the requirement of correlation between risks and benefits differ 
as to the standard of comparison. While some demand a "reasonable" relationship (See Guideline 8 of 
the Council for International Organizations of Medical Science (CIOMS) or "not disproportionate" 
(See Article 16(ii) of the Convention on Human Rights and Biomedicine; and Article 6 of the draft 
Protocol thereto), others require that the potential benefits "justify" (See Section 2.2 of the Guideline 
E6 of the International Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use; CIOMS Guideline 8; Section 3 of the Nuremberg Code; 
Article 3(2)(a) of Directive 2001/20/EC of the European Commission), "exceed" (Section 6 of the 
Nuremberg Code demands that the risks do not exceed "the humanitarian importance of the problem 
to be solved".), or "outweigh[s]" (See Paragraph 18 of the Declaration of Helsinki ) the benefits. 
Some regulations point at the different evaluation of possible risks and benefits for the research 
subject depending on whether the person is ill and in need of treatment or not (See Paragraph 18 of 
the Declaration of Helsinki; CIOMS Guideline 8; Article 6 of the draft Protocol to the Convention on 
Human Rights and Biomedicine).
ii
 See e.g. Martin et al. (1995); Meslin, 1989; Levine, 1978; King, 2000. 
iii
 Martin et al. (1995) are, as far as we know, the first authors to speak of the incommensurability of 
risks and benefits. 
iv
 Important work for developing a conceptual framework to describe risks and benefits has already 
been done by Meslin (1989), Levine (1978) and King (2000).   
v
 See for the concept of covering value: Chang R. Introduction in Chang R (ed.), Incommensurability, 
Incomparability, and Practical Reason. Cambridge, Mass./London: Harvard University Press, 
1997:5. 
vi
 We do not regard diversity as such between IRBs in RBR-assessments as a problem. Here we agree 
with Edwards et al. (2004) who state that some inconsistencies are bad because they are due to 
irrationality, carelessness, the operation of conflicts of conflicting interests, or power struggles within 
committees. But others are not. They argue that particular inconsistencies should be tolerated, or even 
embraced as positively valuable, in that they arise out of meritorious features of the research ethics 
review process. We think that inconsistencies between IRBs will persist even when all IRBs use the 
same conceptual framework for identifying and describing risks and benefits.   
vii
 Prentice ED & Gordon BG, Institutional Review Board Assessment of Risks and Benefits 
Associated with Research. http://onlineethics.org/reseth/nbac/hprentice.html 
viii See: Van Luijn, H.E.M., Musschenga, A.W., Keus, R.B. & Aaronson, N.K. (2005). The evaluation 
of phase II and III cancer clinical trials by Institutional Review Board (IRB) members. Submitted to 
Social Science and Medicine. 
ix
 See: Van Luijn, H.E.M., Aaronson, NK., Keus, R.B. & Musschenga, A.W. (2005).  The evaluation 
of the risks and benefits of phase II cancer clinical trials by Institutional Review Board (IRB) 
members: A case study. Submitted to the Journal of Medical Ethics. 
x
 One of the respondents in the research by Churchill et al. (2003) stated: “Our IRB usually doesn’t 
look at benefit because you can’t assume a benefit, what you have to assume is that it’s safe, that it’s 
not going to hurt the patient. And if you get a benefit out of it, well that’s a plus.” 
xi
 This proposal is similar to the ‘practical solution’ suggested by Martin et al. (1995:9). They propose 
to invite potential subjects, individually or as a community, to provide a judgment regarding the 
acceptability of specified risks in relation to the potential benefits.  
xii
 See: Van Luijn et al., ref. 8.  
 
 
